

Nazim Serdar Turhal M.D.

Personal Information

Date of Birth: April 5th, 1964
Place of Birth: Eskisehir, Turkey
Citizenship: T.R. / U.S.A.
Work Address: Tophanelioglu cad. 13/15 Altunizade Istanbul 81190
Office: Unel Apt 251/5 Bagdat Cad Goztepe Istanbul 34728
Telephone: 90 (216) 3580238-39-40 (pbx)
Fax: 90(216) 3580237
e-mail: turhal@superonline.com

Present Academic Rank and Position:

Professor, Marmara University Medical School
Director, Dept. of Internal Medicine,
Division of Oncology,
Marmara University Hospital

Education:

September 1988 M.D. Univ. of Istanbul
1988-89 Visiting Extern
U.C. San Francisco
San Francisco, Ca.
1989-90 Surgical Intern
Baptist Med. Ctr.
Birmingham, Al.
1990-93 Internal Medicine Resident
Griffin Hospital
(Yale U. Affiliate)
Derby, Ct.
1993-96 Hematology-Oncology Fellow
Mt.Sinai Med. Center
New York, N.Y.
1996-97 Bone Marrow Transplant Fellow
Mt. Sinai Med. Center
New York, N.Y.

Board Certification:

ECFMG:	April 1989	428514-4
FLEX:	June 1990	640405501
Internal Medicine (USA):	November 1996	158365
Oncology (USA):	November 1997	158365
Renewed	November 2007	158365
Internal Medicine (Turkish)	October 1996	42248-46399
Oncology (Turkish)	August 1997	43335-46399
Oncology (European)	January 2000	

Medical Licensure	New York	192309
	Tennessee	034693
Honors:	2000	Technology Transfer Grant Recipient ESMO-NCI Milan
	1994-95	Chief Fellow Mt. Sinai Med. Center
	1987	Representative Class of '89 Warsaw, Poland
	1986	Representative Class of '88 K. City, Kuwait
	1981-82	American Field Service Student Nebraska, USA

Previous Professional Positions and Appointments

Outside of present position I covered numerous physicians and locations in United States for locum tenants appointments since 1997.

Education-Teaching

1. Weekly junior medical student bed side teaching	3 hours	1997-present
2. Quarterly junior medical student oncology lectures	8 hours	1997-present
3. Biweekly Oncology seminars to fellows and residents	4 hours	1997-present
4. Weekly Cancer care meetings with nurses, residents, fellows, psychologists	4 hours	1997-present
5. Weekly junior medical student modular educational activities	48 hours	1999-present

Postdoctoral Fellows Working or Worked For Me

Gul Atalay M.D.	6 years	Med. Oncology
Faysal Dane	4 years	Med. Oncology
Devrim Cabuk	2 years	Med. Oncology
Mehmet Teomete	2 years	Med. Oncology
Mahmut Gumus	3 years	Med. Oncology
Mehmet Aliustaoglu	3 years	Med. Oncology
Meltem Ekenel	3 years	Med. Oncology
Salih İyikesici	3 years	Med. Oncology
Hatice Yildiz	1 year	Data Management
Esen Guzet	2 years	Data Management
Neslihan Doygun	2 years	Data Management
Fatih Ergun	2 years	Data Management
Sibel Çelebioğlu	1 year	Data Management

Institutional, Departmental, and Divisional Administrative Responsibilities, Committee Memberships, and Other Activities

Director	Division of Oncology	1998-present
Credentialing Coordinator	Department of Medicine	2000-present
Faculty of Pharmacy Medical Lectures Coordinator	Medical School	2000
Transfusion Committee	Marmara Univ. Hospital	1999
Hospital Formulary	Marmara Univ. Hospital	1999

Professional and Society Memberships

American Society of Clinical Oncology	1999
European Society of Medical Oncology	1999
Balkan Union of Oncology	1998
American College of Physicians	1998
Turkish Oncological Society	1998

Intramural Presentations

1. Weekly Cancer Grand Rounds	1 hour	1998-
2. Weekly multidisciplinary patient care meetings	3 hours	1998-
3. Weekly oncological pathology meetings	2 hours	1998-
4. Quarterly Internal Medicine grand rounds	1 hour	1998-
5. Weekly Thoracic malignancies multidisciplinary patient care meetings	2 hours	1999-
6. Oncology Nursing Regional Conference	31 hours	2000
7. Surgical Oncology Nursing PhD Program	12 hours	2000
8. Oncology Nursing National Conference	32 hours	2001

Clinical Practice, Interests and Accomplishments

Active member of EORTC Gastrointestinal tumors study group.

Research Interests

Prognostic factors and therapy in Gastrointestinal malignancies

Research Grants Awarded

1. Marmara University research grant for mamosintigraphy project
2. European Society for Medical Oncology Technology Transfer grant

Community Activities

1. "Living with Cancer" television series at Medical Channel 2001- 02
2. "Living with Cancer" column at weekly Gazette Kadikoy 2001- 03

Bibliography

International Peer Reviewed Journal Publications:

- 2.3.1.1. Turhal N**, Sullivan MB, Blakemore WS. Thyroglossal Duct Cyst. *South Med J*, 1990, 83:8, 983-4.
- 2.3.1.2. Turhal N**, DeLuca VA Jr. Ulcerative Colitis and Scleroderma. A coincidental relationship. *J Clin Gastroenterol*. 1994, 18:3, 218-9.
- 2.3.1.3. Turhal NS**, Henehan MD, Kaplan KL. Multiple myeloma: a patient with unusual features including intracranial and meningeal involvement, testicular involvement, organomegaly, and plasma cell leukemia. *Am J Hematol* 1998, 57:1, 51-56.
- 2.3.1.4. Turhal NS**. Cyclosporin A and Imipenem Associated Seizure Activity in Allogeneic Bone Marrow Transplantation Patients. *Journal of Chemotherapy* 1999 11(5): 410-413.
- 2.3.1.5. Turhal NS**, Erdal S, Karacay S. Efficacy of the Treatment to Relieve Mucositis Induced Discomfort. *Supportive Care in Cancer* 2000 8(1): 55-58.
- 2.3.1.6. Turhal NS**. Pancreatic Duct Cell Carcinoma with Positive In-111 Octreotide Uptake. *Journal of Experimental and Clinical Cancer Research* 2000 19(2): 241-244.
- 2.3.1.7. Turhal NS**. Sumatriptan overdose in episodic cluster headache: a case report of overuse without event. *Cephalalgia*. 2001 21:700.
- 2.3.1.8. Turhal NS**, Rand J. Antiphospholipid syndrome in HIV infection - Report of four cases and review of literature. *Allergy & Clinical Immunology International* 2001 13(6):1-4.
- 2.3.1.9. Duman D, Turhal NS, Duman DG, M.D.** Fatal Aplastic Anemia during Treatment with Ketoconazole. *American Journal of Medicine* 2001, 111:9
- 2.3.1.10. Turhal NS**. Two cases of advanced renal cell cancer with prolonged survival of 8 and 12 years. *Japanese Journal of Clinical Oncology* 2002 32(4): 152-153
- 2.3.1.11. Turhal NS**, Gumus M, Atalay G, Aliustaoglu M, Kabakas F, Karamanoglu A, Sengoz M. Outpatient cancer care in a Turkish university hospital. *Journal of BUON* 2002 7(4): 397-398.
- 2.3.1.12. Turhal NS**, Efe B, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M. Patient satisfaction in the outpatients' chemotherapy unit of Marmara University, Istanbul, Turkey: a staff survey. *BMC Cancer* 2002 2(1): 30-33.
- 2.3.1.13. Turhal NS**, Aliustaoglu M, Gurses I, Gumus M, Atalay G, Karamanoglu A, Sengoz M. Neoplastic diseases prevalence in a Turkish university hospital. *Journal of BUON* 2003 8(1): 45-48.

- 2.3.1.14.** Karamanoglu A, Yumuk PF, Gumus M, Aliustaoglu M, Selimen D, Sengoz M, **Turhal NS.** Port needles: Do they need to be removed as frequently in infusional chemotherapy? *Journal of Infusional Nursing* 2003 26(4):239-242.
- 2.3.1.15.** Abacioglu U, Sengoz M, Yumuk F, Salepci T, **Turhal NS.** Cisplatin and etoposide in extra pulmonary small cell cancer. *Tumori* 2003 89(3): 274-277.
- 2.3.1.16.** Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, **Turhal NS.** Outcome of rectum and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital. *J Chemother* 15 (6): 603-606, 2003.
- 2.3.1.17.** **Turhal NS,** Dane F, Dede F, Gumus M, Yumuk PF, Cakalagaoglu F, Savcı D, Karaman M, Gulluoglu B, Turoglu HT. 99m-Tc-MDP Scintimammography to assess angiogenesis in patients with untreated breast cancer. *Anticancer Research.* 24:1999-2006 (2004)
- 2.3.1.18.** Yumuk PF, Gumus M, Ekenel M, Basaran G, Aliustaoglu M, Topal A, **Turhal NS,** N. Attitude Toward Genetic Testing in Turkish Society. *Genetic Testing* 8(2):169-173, 2004
- 2.3.1.19.** Yumuk PF, Aydin SZ, Dane F, Gumus M, Ekenel M, Aliustaoglu M, Karamanoglu A, Sengoz M, **Turhal NS.** The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. *International Journal of Colorectal Disease* 19: 609-610, 2004.
- 2.3.1.20.** Bolukbas FF, Kılıc H, Bolukbas C, Gumus M, Horoz M, **Turhal NS,** Kavali B. Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. *BMC Cancer* 2004, 4:29-32.
- 2.3.1.21.** Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel M, Basaran G, **Turhal NS.** Does the Incidence of Anal Canal Cancers Differ in Moslem Societies? *International Journal of Colorectal Disease, Clinical and Molecular Gastroenterology and Surgery.* 10.1007/s00384-004-0614-4. 2004.
- 2.3.1.22.** Aliustaoglu M, Yumuk PF, Gumus M, Ekenel M, Bolukbas F, Mutlu N, Basaran G, Avsar E, **Turhal NS.** D-Dimer—Can it be a marker for malignant gastric lesions. *Acta Oncologica,* 2004 Dec 43(8) 770-771.
- 2.3.1.23.** Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, **Turhal NS,** Stuart R, Van Cutsem E, D’Haese S, Coens C. Clinical and Psychometric validation of a questionnaire module, The EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. *Eur J Cancer,* 2004 Oct 40(15): 2260-8
- 2.3.1.24.** Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, **Turhal S.** What should be the optimal number of lymph nodes dissected in colorectal Cancer surgery? *Tumori,* 172/03. 11 2004.
- 2.3.1.25.** Yumuk PF, **Turhal NS,** Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T, Aliustaoglu M, Ahiskali R, “Results of paclitaxel (day 1 and 8) and Carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung Cancer”, *BMC Cancer,* (MS:7372801141679098), 2005 March, 21

2.3.1.26. Abacıoğlu U, Yumuk PF, Caglar H, Sengoz M, **Turhal NS**, “Concurrent chemoradiotherapy with low dose weekly Gemcitabine in stage III non-small cell lung cancer.” *BMC Cancer*. 2005 Jul; 6;5:71

2.3.1.27. Onol FF, Tanidir Y, Kotiloglu E, Bayramicli M, **Turhal NS**, Turkeri LN. “Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention.” *Eur Urol*. 2006 Feb; 49(2):7. Epub 2005 Nov 7.

2.3.1.28. Onol FF, Tanidir Y, Kotiloglu E, Bayramicli M, **Turhal NS**, Turkeri LN. “Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention: Part 2.” *Eur Urol* 2006 Mar 49(3):578-80.

2.3.1.29 Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, **Turhal NS**. “HPV DNA frequency and subset analysis in human breast cancer patients normal and tumoral tissue samples.” *J Exp Clin Cancer Res*. 2006 Dec;25(4):515-21.

2.3.1.30 Komurcu S, **Turhal NS**, Altundag K, Atahan L, Turna HS, Manavoglu O, Yavuz AA, Ozkok S, Aliustaoglu M, Altinbas M, Pak Y, Cooper R, Yaylaci M, Demirkan B, Sarihan S, Ozdemir F. “Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish Oncology group trial.” *Eur J Cancer Care (Engl)*. 2007 Jan; 16(1):67-73

2.3.1.31. **Turhal NS**, Popov IP. “Colorectal cancer care in the Balkan countries.” *J BUON* 2005 Apr-Jun;10(2):189-93

2.3.1.32. Atasoy BM, Abacıoglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli A, Basaran G, **Turhal NS**, Sengoz M. “Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.” *J BUON*. 2007 Apr-Jun;12(2):203-8.

2.3.1.33. Celikel C, Eren F, Gulluoglu B, Bekiroglu N, **Turhal NS**. “Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications.” *Pathol Oncol Res*. 2007;13(3):215-26. Epub 2007 Oct 7.

2.3.1.34. Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M, **Turhal NS**. “Vascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and CD34 Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors and Prognostic Impact on Survival.” *Oncology*. 2007 Nov 15;72(1-2):111-117.

2.3.1.35. Yumuk PF, Dane F, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Toprak A, Iyikesici S, Basaran G, **Turhal NS**. Impact of body mass index on cancer development. *J BUON*. 2008 Jan-Mar;13(1):55-59

2.3.1.36. Atasoy BM, Dane F, Yumuk PF, Akgün Z, **Turhal NS**, Abacıoğlu U, Sengöz M. Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally advanced nasopharyngeal carcinoma. *J BUON*. 2008 Jan-Mar;13(1):43-50.

2.3.1.37. Koldas M, Gumus M, Seker M, Seval H, Huyla K, Dane F, Kural A, Gumus A, Salepci T. and **NS Turhal**, "Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer," *Clin Lung Cancer.*, 9(2), 112-115 (2008).

2.3.1.38. Kefeli U, Dane F., Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, and **NS Turhal**, "Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer," *Eur J Cancer Care (Engl)*, 18(2), 191-194 (2009).

2.3.1.39. Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete M, and **NS Turhal**, "A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion," *J BUON*, (2009). [basımda]

National (Turkish) Publications:

- 2.3.2.1. Turhal NS.** “Metastatik meme kanseri yaygın kemik metastazlarında tedavi”, *Kanser Gündemi, Türkiye Kanserle Savaş Vakfı*, 1998 3(3): 118-121.
- 2.3.2.2. Turhal NS.** “Yetişkin kanser hastalarında transfüzyon tedavisi yaklaşımları” *Damla, Kan Merkezleri ve Transfüzyon Derneği Bülteni*, 1998 22:4-7.
- 2.3.2.3. Turhal NS.** “Meme kanserinin biyolojik tedavisinde: Herceptin, *Academic Hospital* 1998 4:16-18.
- 2.3.2.4. Turhal NS, Tanju P, Pekin S.** “Serviks kanseri etyolojisine yönelik standart ve gelecek vadeden tarama yaklaşımları” *Hekimler Birliği Vakfı, Türkiye Klinikleri, Jinekolojik Obstetrik*, 1999 9(3): 215-220.
- 2.3.2.5. Turhal NS, Akdas A.** “Prostat kanserinde gen tedavisi uygulaması ve sorunları” *Üroloji Bülteni* 1999 10(1): 5-11.
- 2.3.2.6. Turhal NS.** “Lokal ileri evre meme kanserinde neoadjuvan ve adjuvan kemoterapi” *Hematoloji-Onkoloji, Güncel Derleme Dergisi*, 2001 3(2):123-127.
- 2.3.2.7. Atalay G, Turhal NS.** “Kanserli hastalarda ağrı dışı semptomların palyasyonu: Hıçkırık, disfaji ve dispepsi” *Hematoloji-Onkoloji, Güncel Derleme Dergisi*, 2001, 3(3): 236-239.
- 2.3.2.8. Kaya H, Kotiloglu E, Sengoz M, Turhal S, Uneri C.** “Aggressive fibromatosis: A case report”. *Journal of Marmara University Dental Faculty*, 2001 Vol 4(3): 288-90.
- 2.3.2.9. Basaran G, Ekenel M, Demirkalem P, Cakır T, Gulluoglu B, Gumus M, Dane F, İyikesici S, Kaya H, Yumuk PF, Turhal NS.** “Evre 1 (T1 N0 M0) Meme Kanseri: Patolojik özellikler ve klinik sonuçlar”, *Türk Onkoloji Dergisi*, 2004 19(2):53-57.
- 2.3.2.10. Yumuk PF, İyikesici MS, Gumus M, Aliustaoglu M, Dane F, Basaran G, Ekenel M, Abacıoğlu U, Turhal NS.** “Lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri hastalarının değerlendirilmesi, Marmara Üniversitesi deneyimi”, *Türk Onkoloji Dergisi*, 2004 19(3): 106-110.
- 2.3.2.11. Yumuk PF, Turhal NS.** “Bir medikal onkolog perspektifinden muskuloskeletal hastalıklarda nükleer tıp” *Turkish Journal of Nuclear Medicine* 2004, Baskıda
- 2.3.2.12. Atasoy BM, Dane F, Sarı M, Yumuk PF, Akgün Z, Turhal NS, Abacıoğlu U, ve Şengöz M,** “Lokal ileri evre skuamöz hücreli baş ve boyun kanserinde sisplatinle eş zamanlı kemoradyoterapi: Yan etki ve uygulanabilirlik analizi,” *Türk Onkoloji Dergisi*, 23, 1-11 (2008).
- 2.3.2.13. Atasoy BM, Dane F, Çağlar H, Tezcanlı E, Cingi A, Abacıoğlu U, Turhal NS, ve C Yeğen,** “Rezeke edilebilir lokal ileri evre rektum kanserinde floroprimidin bazlı

kemoterapi ile eş zamanlı ameliyat öncesi radyoterapi,” *Türk Onkoloji Dergisi*, 23, 163-171 (2008).

Citations:

- 2.3.3.1. Author(s):** Kim JH; Lee SH; Park J; Kim HY; Lee SI; Nam EM; Park JO; Kim K; Jung CW; Im YH; Kang WK; Lee MH; Park K. **Title:** Extrapulmonary small-cell carcinoma: a single-institution experience. **Source:** JAPANESE JOURNAL OF CLINICAL ONCOLOGY 2004, Vol 34, Iss 5, pp 250-254
- 2.3.3.2.** Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L, Hatem F, Huang J, Anthony S. **Title:** Small Cell Carcinoma of the Prostate: An Immunohistochemical Study. **Source:** American Journal of Surgical Pathology. 30(6):705-712, June 2006
- 2.3.3.3. Author(s):** D. Demellawy, A. Samkari, M. Sur, F. Denardi, S. Alowami. **Title:** Primary small cell carcinoma of the cecum. **Source:** Annals of Diagnostic Pathology, Volume 10, Issue 3, Pages 162-165
- 2.3.3.4. Author(s):** Young HK, Ryuk K, Ghap JJ, Myung HR, Sang YH, Hyuk CK, Jin SJ, Tae BS, Jong YO, Ki NL. **Title:** Extrapulmonary small-cell carcinoma of the liver **Source:** Journal of Hepato-Biliary-Pancreatic Surgery Oct. 2004 Vol 11, Num 5,
- 2.3.3.5. Author(s):** Vogelsang H., Siewert I.R. **Title:** Neuroendokrine Tumors of the hindgut **Source:** Best Practice & Research Clinical Gastroenterology, Volume 19, Issue 5, Pages 739-751
- 2.3.3.6. Author(s):** A. Ferlito, K. Devaney, A. Rinaldo **Title:** Neuroendocrine neoplasms of the larynx: Advances in identification, understanding, and management **Source:** Oral Oncology, Volume 42, Issue 8, Pages 770-788
- 2.3.3.7. Author(s):** E. Kurt, C. Sezgin, T. Evrensel, U. Yalcinkaya, O. Kanat, A. Veral, M. Demiray, M. Arslan, B. Karabulut, I. Ercan, E. Goker, O. Manavoglu **Title:** Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma **Source:** International Journal of Clinical Practice; 2005; 59 (5), 537–543.
- 2.3.3.8. Author(s):** Chen JW , Yuan L , Hu HH **Title:** Small cell undifferentiated carcinoma in the epididymis **Source:** Chinese Medical Journal 2005; 118(16): 1402-1404
- 2.3.3.9. Author(s):** Author(s): Vogelsang H., Siewert I.R. **Title:** Neuroendokrine Tumoren des Kolons und Rektums, Mit Ausnahme der Appendix **Source:** MULTI MODALITY TREATMENT RESULTS Onkologe 2004-10:1069-1078
- 2.3.3.10. Author(s):** Kim KO; Lee HY; Riyu MH; Shin SJ; Kim MK; Lee KH; Hyun MS; Bae HS; Ryoo HM. **Title:** Extrapulmonary small-cell carcinoma **Source:** J Korean Med. Sci. 2006; 21: 833-7
- 2.3.3.11. Author(s):** Lee SS; Lee JL; Riyu HM; Chang HM; Tae WK; Jung SL; Jang SJ; Khang SK; Kang YK **Title:** Extrapulmonary small cell carcinoma: Single center experience with 61 patients **Source:** Acta Oncologica, Volume 46, Issue 6 2007 , pages 846 – 851
- 2.3.3.12. Author(s):** M. Yashi, F. Terauchi, A. Nukui, M. Ochi, M. Yuzawa, Y. Hara, T. Morita **Title:** Small-cell neuroendocrine carcinoma as a variant form of prostate cancer

recurrence: A case report and short literature review **Source:** Urologic Oncology: Seminars and Original Investigations, Volume 24, Issue 4, Pages 313-317

2.3.3.13. Author(s): A Barbeaux, L Duck, B Weynand, G Desuter, M Hamoir, V Gregoire, J Baurain, J Machiels **Title:** Primary combined squamous and small cell carcinoma of the larynx: report of two cases and discussion of treatment modalities **Source:** Oto-Rhino-Laryngology, 2006; Volume 263, Number 8 / 786-790

2.3.3.14. Author(s): L Kovac, M Gjuric, S Branica, K Dawidowsky, S Seiwert **Title:** Small cell neuroendocrine carcinoma in the petrous apex **Source:** Journal of Laryngology & Otology (2006), 120: 74-76

2.3.3.15. Author(s): N. Güler, P. Yumuk, D. Ilguy, V. Olgac, J. Greer **Title:** Limited Painful Mouth Opening **Source:** Journal of Oral and Maxillofacial Surgery, Volume 63, Issue 8, Pages 1201-1205

2.3.3.16. Author(s): R. Simon, P. Bourne, Q. Yang, B. Spaulding, P. di Sant'Agnese, H. Wang, H. Xu **Title:** Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not **Source:** Human Pathology, Volume 38, Issue 8, Pages 1178-1183

2.3.3.17. Author(s): WT hseh, WC Su, FF Chen **Title:** Experiences of Radiotherapy on Extrapulmonary Small Cell Carcinoma **Source:** 2005, 2, 24.

2.3.3.18. Author(s): DE Demellawy, MA Khalifa, N Ismiil, S Wong, Z Ghorab **Title:** Primary colorectal small cell carcinoma: A clinicopathological and immunohistochemical study of 10 cases **Source:** Diagn Pathol. 2007; 2: 35.

2.3.3.19. Author(s): Yuan ZY, Guan ZZ, Zhou ZM, Xia Y, Huang WZ, Yang XL. **Title:** Extrapulmonary small cell carcinoma in 52 patients **Source:** Chinese Medical Journal 2006 Sep; 25(9): 1131-3.

2.3.3.20. Author(s): G. Lima, I. Varkarakis, M. Allaf, S. Fine, L. Kavoussi **Title:** Small cell carcinoma of epididymis: Multimodal therapy **Source:** Urology, Volume 66, Issue 2, Pages 432.e19-432.e20

2.3.3.21. Author(s): AF Korcum; G Aksu; M Ozdogan; G Erdogan; O Taskin **Title:** Stage I small cell carcinoma of the endometrium: survival and management options **Source:** Acta Obstetrica et Gynecologica Scandinavica, 200

2.3.3.22. Author(s): EB. Rubenstein, DE Peterson, M Schubert, D Keefe, D McGuire, J Epstein, LS. Elting, PC. Fox, C Cooksley, ST. Sonis, **Title:** Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis **Source:** Cancer 2004 Volume 100, Issue S9 , Pages 2026 – 2046

2.3.3.23. Author(s): PJ Hancock, JB Epstein, GR Sadler **Title:** Oral and dental management related to radiation therapy for head and neck cancer **Source:** J Can Dent Assoc 2003, Vol 69 No: 9, 585-590

- 2.3.3.24. Author(s):** DB. McGuire, ME Correa, J Johnson, P Wienandts, **Title:** The role of basic oral care and good clinical practice principles in the management of oral mucositis **Source:** Supportive Care in Cancer 2006, Vol 14, No 6, 541-547
- 2.3.3.25.** Palliative Medicine Handbook 3. Dr Ian Back 2001
- 2.3.3.26. Author(s):** DJ Harris, MT Knobf, **Title:** Assessing and Managing Chemotherapy-Induced Mucositis Pain **Source:** Clinical Journal of Oncology Nursing, 2004, Vol 8, No 6, 622-628
- 2.3.3.27. Author(s):** EMB Costa; MZ Fernandes; LB Quinderé; LB Souza; LP Pinto **Title:** Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia **Source:** Pesqui. Odontol. Bras. 2003;17(2):147-50
- 2.3.3.28. Author(s):** D. Alterio, B. Jereczek-Fossa, G. Zuccotti, M. Leon, E. Omodeo Sale, M. Pasetti, T. Modena, P. Perugini, L. Mariani, R. Orecchia **Title:** Tetracaine oral gel in patients treated with radiotherapy for head-and-neck cancer: Final results of a phase II study **Source:** International Journal of Radiation Oncology*Biophysics*Physics, Volume 64, Issue 2, Pages 392-395
- 2.3.3.29. Author(s):** B Quinn, C.M.J. Potting, R Stone, N.M.A. Blijlevens, M Flidner, A Margulies, L Sharp **Title:** Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients **Source:** Eur J Cancer. 2007 doi: 10.1016 / j.ejca. 2007. 09. 014
- 2.3.3.30. Author(s):** MC Guedes; R Weber; MVS Gomez; RB Neto; CG Peralta; RF Bento **Title:** Influence of evoked compound action potential on speech perception in cochlear implant users **Source:** Rev. Bras. Otorrinolaringol. vol.73 no.4 São Paulo July/Aug. 2007
- 2.3.3.31. Author(s):** AP Chaves; JAP Gomes; ALH Lima **Title:** Ocular changes induced by chemotherapy **Source:** Arq Bras Oftalmol. 2007;70(4):718-25
- 2.3.3.32. Author(s):** Debra J Harris **Title:** Cancer treatment-induced mucositis pain: strategies for assessment and management **Source:** Dove Medical Press, Sepp 2006, Vol 2, Iss 3, Page 251-258
- 2.3.3.33. Author(s):** J. M. Blazeby , C. Metcalfe , J. Nicklin , C. P. Barham , J. Donovan, D. Alderson **Title:** Association between quality of life scores and short-term outcome after surgery for cancer of the oesophagus or gastric cardia **Source:** British Journal of Surgery , 2005 Volume 92, Issue 12 , Pages 1502 – 1507
- 2.3.3.34. Author(s):** Y. Dan, J. So, K. Yeoh **Title:** Endoscopic Screening for Gastric Cancer. **Source:** Clinical Gastroenterology and Hepatology, Volume 4, Issue 6, Pages 709-716
- 2.3.3.35. Author(s):** Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovanni M, Etienne PL, Mitry E, Seitz JF, Rougier P, Girault C, Bedenne L, **Title:** Longitudinal quality of life study in patients with metastatic gastric cancer. **Source:** Gastroenterol Clin Biol 2005;29:1113-1124

- 2.3.3.36. Author(s):** Scurtu R, Groza N, Otel O, Goia A, Funariu G **Title:** Quality of Life in Patients with Esophagojejunal Anastomosis after total Gastrectomy for Cancer. **Source:** Rom J Gastroenterol 2005, Vol 14. No 4, 367-372
- 2.3.3.37. Author(s):** Sadighi S, Hohagheghi MA, Montazeri A, Sadighi Z **Title:** Quality of life in patients with advanced gastric cancer: a randomized trial comparing Docetaxel Cisplatin 5-FU (TCF) with Epirubicin Cisplatin 5-FU (ECF). **Source:** BMC Cancer 2006; 1471/2407/6/274
- 2.3.3.38. Author(s):** Olivier B **Title:** Comment améliorer le pronostic du cancer gastrique en France? **Source:** Gastroenterol Clin Biol 2005;29:7-10
- 2.3.3.39. Author(s):** P. Costa, J. Carraca, A. Sofia Brito, N. Figueiredo, P. Lages **Title:** Avaliação multifatorial da qualidade de vida em doentes gastrectomizados por cancro gástrico. estudo piloto de métodos de avaliação **Source:** J Port Gastreterol 2006, 13:174-180
- 2.3.3.40. Author(s):** Satoshi M, Adrian AK, Akira T, Yasuhiro K, Takanori M, Junichi S **Title:** Assessment and data analysis of health-related quality of life in clinical trials for gastric cancer treatments **Source:** Gastric Cancer 2006, Vol 9, No 4, 254-261
- 2.3.3.41. Author(s):** T Conroy, F Marchal, JM. Blazeby **Title:** Quality of Life in Patients with Oesophageal and Gastric Cancer: An Overview **Source:** Oncology 2006;70:391-402,
- 2.3.3.42. Author(s):** CC Huang , HH Lien , YC Sung , HT Liu , WC Chie **Title:** Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22 **Source:** Psycho-Oncology, Volume 16, Issue 10 , Pages 945 – 949
- 2.3.3.43. Author(s):** JM Bae, S Kim, YW Kim, KW Ryu, JH Lee, JH Noh, TS Sohn, SK Hong, SM Park, CH You, JH Kim, MK Lee, YH Yun **Title:** Health-related quality of life among disease-free stomach cancer survivors in Korea **Source:** Quality of Life Research, 2006, Vol 15 No: 10 / 1587-1596
- 2.3.3.44. Author(s):** P. Lagergren, P. Fayers, T. Conroy, H. Stein, O. Sezer, R. Hardwick, E. Hammerlid, A. Bottomley, E. Van Cutsem, J. Blazeby **Title:** Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago–gastric junction and the stomach. **Source:** European Journal of Cancer, Volume 43, Issue 14, Pages 2066-2073
- 2.3.3.45. Author(s):** Y. Yun, S. Kim, K. Lee, S. Park, Y. Kim **Title:** Age, sex, and comorbidities were considered in comparing reference data for health-related quality of life in the general and cancer populations **Source:** Journal of Clinical Epidemiology, Volume 60, Issue 11, Pages 1164-1175
- 2.3.3.46. Author(s):** R Pai, C Lin, T Tran, A Tarnawski **Title:** Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation **Source:** Biochemical and Biophysical Research Communications 2005, Vol 331, Iss 4, 17, Pages 984-992

- 2.3.3.47. Author(s):** I Wolf, S Sadetzki, H Kanety, Y Kundel, C Pariente, N Epstein, B Oberman, R Catane, B Kaufman, I Shimon, **Title:** Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients **Source:** Cancer, 2006, Vol 106, Iss 4, Pages 966-973
- 2.3.3.48. Author(s):** Dai Shida, Joji Kitayama, Ken Mori, Toshiaki Watanabe and Hirokazu Nagawa **Title:** Transactivation of Epidermal Growth Factor Receptor Is Involved in Leptin-Induced Activation of Janus-Activated Kinase 2 and Extracellular Signal-Regulated Kinase 1/2 in Human Gastric Cancer Cells **Source:** Cancer Research 65, 9159-9163, October 15, 2005
- 2.3.3.49. Author(s):** M Koda, M Sulkowska, LK Koda, E Surmacz, S Sulkowski, **Title:** Overexpression of the obesity hormone leptin in human colorectal cancer **Source:** Journal of Clinical Pathology 2007;60:902-906
- 2.3.3.50. Author(s):** ER Ropelle, JR Pauli, KG Zecchin, M Ueno, CT Souza, J Morari, MC Faria, LA Velloso, MJA Saad, JBC Carvalheire **Title:** A Central Role For Neuronal Amp Activated Protein Kinase (Ampk) In Cancer-Induced Anorexia **Source:** Endocrinology 2007, Vol. 148, No. 11 5220-5229
- 2.3.3.51. Author(s):** Douglas A Corley **Title:** Obesity and the rising incidence of oesophageal and gastric adenocarcinoma **Source:** Gut 2007;56:1493-1494
- 2.3.3.52. Author(s):** M Koda, M Sulkowska, L Kanczuga-Koda, S Cascio, G Colucci, A Russo, E Surmacz, S Sulkowski **Title:** Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 α in human colorectal cancer **Source:** Annals of Oncology 2007 18(Supplement 6):vi16-vi19
- 2.3.3.53. Author(s):** Petersen SL; Wagner A; Gimsing P. **Title:** Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. **Source:** AMERICAN JOURNAL OF HEMATOLOGY 1999, Vol 62, Iss 4, pp 228-233.
- 2.3.3.54. Author(s):** Wellwood J; Taylor K; Wright S; Bentley M; Hill G; Phan H; Norris D; Livsey R. **Title:** Relapsed plasma cell leukaemia presenting with aggressive extramedullary plasmacytomas in the meninges and testis - A missed opportunity for induction CNS prophylaxis. **Source:** LEUKEMIA & LYMPHOMA 2002, Vol 43, Iss 4, pp 893-896
- 2.3.3.55. Author(s):** Hayes-Lattin B; Blanke CD; Deloughery TG. **Title:** Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: A case report. **Source:** AMERICAN JOURNAL OF HEMATOLOGY 2003, Vol 73, Iss 2, pp 131-134
- 2.3.3.56. Author(s):** C Pontikoglou; C Fragos; E Kolyvaki; G Samonis ^a; GD Eliopoulos; HA.Papadaki. **Title:** Multiple myeloma involving the central nervous system: a report of two cases with unusual manifestations **Source:** Leukemia and Lymphoma, Volume 46, Issue 5 May 2005 , pages 737 – 741

2.3.3.57. Author(s): JT Rosal, I Aleman, J Ronquillo, I Puerto, L Rodriguez **Title:** Glioblastoma multiforme arising in the setting of multiple myeloma **Source:** Haema 2005; 8(4):704-706

2.3.3.58. Author(s): Asherson RA; Cervera R. **Title:** Antiphospholipid antibodies and infections. **Source:** ANNALS OF THE RHEUMATIC DISEASES 2003, Vol 62, Iss 5, pp 388-393

2.3.3.59. Author(s): Cervera R; Asherson RA; Acevedo ML; Gomez-Puerta JA; Espinosa G; de la Red G; Gil V; Ramos-Casals M; Garcia-Carrasco M; Ingelmo M; Font J. **Title:** Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. **Source:** ANNALS OF THE RHEUMATIC DISEASES 2004, Vol 63, Iss 10, pp 1312-1317.

2.3.3.60. Author(s): Ramos-Casals M; Cervera R; Lagrutta M; Medina F; Garcia-Carrasco M; de la Red G; Bove A; Ingelmo M; Font J. **Title:** Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): Description of 82 cases. **Source:** CLINICAL INFECTIOUS DISEASES 2004, Vol 38, Iss 7, pp 1009-1016

2.3.3.61. Author(s): Asherson RA; Shoenfeld Y. **Title:** Human immunodeficiency virus infection, antiphospholipid antibodies, and the antiphospholipid syndrome. **Source:** JOURNAL OF RHEUMATOLOGY 2003, Vol 30, Iss 2, pp 214-219

2.3.3.62. Author(s): P Hopwood **Title:** Psychosocial aspects of risk communication and mutation testing in familial breast-ovarian cancer **Source:** Current Opinion in Oncology. July 2005, 17(4):340-344,

2.3.3.63. Author(s): A MacArthur, CD Bajdik, JJ Spinelli, C Kim-Sing, RP Gallagher **Title:** Predicting interest in genetic counseling and testing for cancer susceptibility: The British Columbia Family Cancer Survey Pilot Study **Source:** BC Medical Journal Volume 48, Number 5, June 2006, page 222-225

2.3.3.64. Author(s): U. Gallkowski, H Muller, S. Manekeller, J. Boese-Landgraf, S. Ridwelski **Title:** Umgang und Pflege implantierter Portkathetern bei Tumorpataienten – ein interdisziplinäres Problem **Source:** Surgical Oncology

2.3.3.65. Author(s): ÖU Yesilbalkan **Title:** Onkoloji Hastalarında Sık Kullanılan Venöz Giriş Aracı: İmplant Port Kateter **Source:** C.Ü. Hemşirelik Yüksek Okulu Dergisi 2005, 9 (2)

2.3.3.66. Author(s): KW Jauch, W Schregel, Z Stanga **Title:** 9 Technik und Probleme der Zugänge in der parenteralen Ernährung **Source:** Aktuel Ernaehr Med 2007; 32, Supplement 1: S41-S53

2.3.3.67. Author(s): N. Villanueva; E. Esteban; I. Muñoz J. Vieitez¹ L. Olay; I. Jimenez; P. Jimenez; M. Luque; B. Llorente; M. Capelan; E. Estrada; Y. Fernández; J. Fra; A. J. Lacave **Title:** Radioterapia torácica con 70 Gy concurrente con docetaxel o paclitaxel semanal tras quimioterapia de inducción en pacientes con carcinoma de pulmón no

microcítico localmente avanzado. Estudio prospectivo de tolerancia y eficacia **Source:** Oncología (Barc.) v.29 n.10 Madrid dic. 2006

2.3.3.68. Author(s): EE Vokes, J. E. Herndon, M. J. Kelley, D. Watson, M. G. Cicchetti, M. R. Gren **Title:** Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial **Source:** Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7005

2.3.3.69. Author(s): YS Gouda, HM Kohail, NA Eldeeb, AM Omar, MM El-Geneidy, YM Elkerm **Title:** Randomized Study of Concurrent Carboplatin, Paclitaxel, and Radiotherapy Induction Chemotherapy in Patients with Locally Advanced Non Small cell lung cancer **Source:** Journal of the Egyptian Nat. Cancer Inst. March 2006, Vol 18, No 1, 73-81

2.3.3.70. Author(s): Rossi P; Di Lorenzo G; Formisano R; Buzzi MG. **Title:** Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache patients. **Source:** HEADACHE 2004, Vol 44, Iss 7, pp 713-718

2.3.3.71. Author(s): K. Paemeleire, A. Bahra, S. Evers, MS Matharu, PJ Goadsby, **Title:** Medication-overuse headache in patients with cluster headache **Source:** NEUROLOGY 2006;67:109-113

2.3.3.72. Author(s): S Sitalakshmi, R Karuna, D Prema **Title:** Do plasma D-dimer levels correlate with disease stage in colonic carcinoma? **Source:** Indian Journal of Surgery, 2006, Vol 68, Iss 6, Page 306-309

2.3.3.73. Author(s): JIN Xiao-shi **Title:** The research on the changes of the D-dimer and fibrinogen concentrations in the patients with colorectal carcinoma **Source:** Journal of Tianjin Medical University 2006, Vol. 12. No. 3 Sep. 404-405

2.3.3.74. Author(s): E Renoult, C Buteau, V Lamarre, N Turgeon, B Tapiero **Title:** Infectious risk in pediatric organ transplant recipients: Is it increased with the new immunosuppressive agents? **Source:** Pediatric Transplantation 2005, 9 (4), 470-479

2.3.3.75. Author(s): Wang HX, Ji SQ, Zhu L, Liu J, Xue M, Ding L, Duan LN, Yan HM, Chen HR **Title:** Neurological Complications Following Haploidentical Bone Marrow Transplantation **Source:** Journal of Experimental Hematology 2005, Vol 13, No 6, 1128-1130

2.3.3.76. Author(s): Atesci FC; Baltalarli B; Oguzhanoglu NK; Karadag F; Ozdel O; Karagoz N. **Title:** Psychiatric morbidity among cancer patients and awareness of illness. **Source:** SUPPORTIVE CARE IN CANCER 2004, Vol 12, Iss 3, pp 161-167

2.3.3.77. Author(s): Mehta VK, Poen J, Ford J, Oberhelman H, Vierra MA, Bastidas AJ, Fisher GA. **Title:** Protracted Venous Infusion 5-Fluorouracil With Concomitant Radiotherapy Compared With Bolus 5-Fluorouracil for Unresectable Pancreatic Cancer **Source:** American Journal of Clinical Oncology. 2001, 24(2):155-159,

2.3.3.78. Author(s): R Wilkowski, M Wolf, V Heinemann **Title:** Primary Advanced Unresectable Pancreatic Cancer **Source:** Pancreatic Cancer, 2007, Vol 177, Iss 80-15, Pages 79-93

2.3.3.79. Author(s): S Höcht, T Wiegel, A Siegmann, W Hinkelbein **Title:** Radiochemotherapy in Unresectable Pancreatic Cancer **Source:** Front Radiat Ther Oncol. 2004, Vol 38, pp 87-93.

2.3.3.80. Author(s): GJ Chang, MAR Bigas, JM Skibber, VA Moyer **Title:** Lymph Node Evaluation and Survival After Curative Resection of Colon Cancer: Systematic Review **Source:** Journal of the National Cancer Institute 2007 99(6):433-441

2.3.3.81. Author(s): P Greco, S Andreola, G Magro, F Belli, G Giannone, GF Gallino, E Leo **Title:** Potential pathological understaging of pT3 rectal cancer with less than 26 lymph nodes recovered: a prospective study based on a resampling of 50 rectal specimens **Source:** Virchows Archiv, 2006, Vol 449, No 6, Page 647-651

2.3.3.82. Author(s): Caronna R; Cardi M; Sammartino P; Mangioni S; Pittau G; Scozzafava S; Catinelli S; Chirletti P; Stipa V. **Title:** Functional results of a personal technique of reconstruction after pancreaticoduodenectomy. **Source:** JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2003, Vol 22, Iss 4, pp 187-189

2.3.3.83. Author(s): JK Aronson **Title:** A worldwide yearly survey of new data and trends **Source:** Elsevier, Side Effects of Drugs Annual 26,

2.3.3.84. Author(s): J Shuster **Title:** ISMP Adverse Drug Reactions Reports **Source:** Hospital Pharmacy, 2002, Volume 37, Number 3, pp 242-249, 333

2.3.3.85. Author(s): LCS Martinez, NEC Ceballos, EM Carrillo **Title:** To know the survival in patients with renal cell carcinoma **Source:** Collegio Mexicano de Urologia, 2002, Vol 17, No 4, pp 187-192

2.3.3.86. Author(s): DE Rapp, WS Reynolds, A Lucioni, GT Bales **Title:** Surgical technique using AdVance™ Sling placement in the treatment of post-prostatectomy urinary Incontinence **Source:** International Braz J Urol. 2007, Vol. 33 (2): 231-237,

2.3.3.87. Author(s): G Barbagli, M Lazeri **Title:** Surgical technique using AdVance™ Sling placement in the treatment of post-prostatectomy urinary Incontinence **Source:** International Braz J Urol. 2007, Vol. 33 (4): 461-469

2.3.3.88. Author(s): S Suryanarayanan **Title:** Design, development, and characterization of a prototype digital mammography system **Source:** Georgia Institute of Technology, 2006

2.3.3.89. Author(s): Garsten J. **Title:** The Yale-Affiliated gastroenterology program - Personal note. **Source:** JOURNAL OF CLINICAL GASTROENTEROLOGY 1996, Vol 22, Iss 4, pp 255-260.

- 2.3.3.90. Author(s):** Lier H; Thees C; Nadstawek J. **Title:** Anaesthesia and epilepsy - a review. **Source:** ANASTHESIOLOGIE & INTENSIV MEDIZIN 2003, Vol 44, Iss 12, pp 857-868
- 2.3.3.91. Author(s):** Lorenzo OA; Fernandez-Monras F; Arago JV; Abaurrea FR. **Title:** Progressive systemic sclerosis and inflammatory bowel disease. **Source:** REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS 2002, Vol 94, Iss 6, pp 372-373.
- 2.3.3.92. Author(s):** Epstein JB; Truelove EL; Oien H; Allison C; Le ND; Epstein MS. **Title:** Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. **Source:** ORAL ONCOLOGY 2001, Vol 37, Iss 8, pp 632-637.
- 2.3.3.93. Author(s):** Moncouey X; Hamon R; Diebold MD; Coussinet S; Pennaforte JL; Thieffn G; Cadiot G. **Title:** Systemic sclerosis and ulcerative colitis. **Source:** GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 2001, Vol 25, Iss 3, pp 324-325
- 2.3.3.94. Author(s)** Ulusakarya A; Youssef A; Bayle C; Vantelon JM; Munck JN. **Title:** Plasma cell meningitis after an autograft in a patient with multiple myeloma. **Source:** LEUKEMIA & LYMPHOMA 1999, Vol 34, Iss 5-6, pp 633-634
- 2.3.3.95. Author(s):** Leleu X; Jouet JP; Plantier I; Zandecki M; Lai JL; Mucha D; Lejeune JP; Bauters F; Facon T. **Title:** Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases. **Source:** LEUKEMIA 1999, Vol 13, Iss 2, pp 307-309.
- 2.3.3.96.** Mohammadine E; Benabdellah W; Lahlou MK; Benamr S; Essadel H; Belmahi AM; Abbassi A; Ukkas A; Taghy A; Chad B; Zizi A; Belmahi A. **Title:** About a pseudo neoplastic colic stenosis preceding systemic scleroderma. **Source:** ANNALES DE GASTROENTEROLOGIE ET D HEPATOLOGIE 1997, Vol 33, Iss 3, pp 127-131.
- 2.3.3.97. Author(s):** Heymann WR. **Title:** Advances in the cutaneous manifestations of thyroid disease. **Source:** INTERNATIONAL JOURNAL OF DERMATOLOGY 1997, Vol 36, Iss 9, pp 641-645
- 2.3.3.98. Author(s):** Kilchenstein W; Muller OA. **Title:** Progressive systemic scleroderma - Involvement of the gastrointestinal tract. **Source:** AKTUELLE RHEUMATOLOGIE 1996, Vol 21, Iss 4, pp 184-189
- 2.3.3.99. Author(s):** HEYMANN WR. **Title:** CUTANEOUS MANIFESTATIONS OF THYROID-DISEASE. **Source:** JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 1992, Vol 26, Iss 6, pp 885-902.
- 2.3.3.100. Author(s):** Rohwer, N. ve ark. "HIF-1alpha determines the metastatic potential of gastric cancer cells," *Br J Cancer.*, **100(5):**772-81 (2009).
- 2.3.3.101. Author(s):** Casado, E. ve ark. "UFT (tegafur-uracil) in rectal cancer," *Ann Oncol.*, **19(8):**1371-8, Review, (2008).

- 2.3.3.102. Author(s):** 1. Akil, N. ve ark., “High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study,” *Br J Cancer*, **5;99(3)**:404-7 (2008)
- 2.3.3.103. Author(s):** Liang, W. Ve ark., “Hypothetic association between human papillomavirus infection and breast carcinoma,” *Med Hypotheses.*, **70(2)**:305-7 (2008).
- 2.3.3.104 Author(s):** Cazzaniga, M. ve ark., “Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis,” *Breast Cancer Res Treat.*, **114(3)**:599-605 (2009).
- 2.3.3.105. Author(s):** Mendizabal-Ruiz, A.P. ve ark., “Low frequency of human papillomavirus DNA in breast cancer tissue,” *Breast Cancer Res Treat.*, **114(1)**:189-94 (2009).
- 2.3.3.106. Author(s):** Amarante, M.K. ve ark., “The possible involvement of virus in breast cancer,” *J Cancer Res Clin Oncol.*, **135(3)**:329-37 (2009).
- 2.3.3.107. Author(s):** Sun, L. Ve ark., “In GFP with high risk HPV-18E6 fusion protein expressed 293T and MCF-7 cells, the endogenous wild-type p53 could be transiently phosphorylated at multiple sites,” *J Exp Clin Cancer Res.*, **27**:35 (2008).
- 2.3.3.108. Author(s):** He, Q. Ve ark., “The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma,” *Mol Biol Rep.*, **36(4)**: 807-12 (2009).
- 2.3.3.109. Author(s):** Koppie, T.M. ve ark., “Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?,” *Cancer.*, **107(10)**:2368-74 (2006).
- 2.3.3.110. Author(s):** Govindarajan, A. ve ark., “Lymph node evaluation in early-stage colon cancer,” *Clin Colorectal Cancer.*, **7(4)**:240-6 (2008).
- 2.3.3.111. Author(s):** York Health Economics c o n s o r t i u m, Department Of Health, Bowel Cancer Services: Costs and Benefits Literature Review, York Health, April 2007
- 2.3.3.112. Author(s):** Tzanopoulou, S. ve ark. “Synthesis, characterization, and biological evaluation of M(I)(CO)(3)(NNO) complexes (M = Re, Tc-99m) conjugated to 2-(4-aminophenyl) benzothiazole as potential breast cancer radiopharmaceuticals”, *Journal Of Medicinal Chemistry*, **49**, 5408-5410 (2006).
- 2.3.3.113. Author(s):** Richardson, G. ve ark. “Chemotherapy induced diarrhea,” *J Oncol Pharm Pract.*, **13(4)**:181-98. Review (2007).

International Abstracts:

- 2.4.1.1.** Vassallo P, Pearson WN, **Turhal N**. The diagnostic role of transesophageal echo (TEE) in patients with pulmonary emboli but no obvious embolic source. *Chest*, 1993, 104:2, 141S.
- 2.4.1.2.** Terk M, **Turhal N**, Mandeli J, et al: Long-term follow-up of combined modality therapy for unresectable pancreatic cancer. *Proceedings of American Society of Clinical Oncology* 1996, 16, 307a.
- 2.4.1.3.** **Turhal NS**, Bruckner HW. Neoadjuvant treatment of gastric and gastroesophageal cancers. *Journal of Balkan Union of Oncology* 1998, 3:49.
- 2.4.1.4.** **Turhal NS**, Isola L, Scigliano E, Vlachos A, Fruchtman S. A study of cyclosporine A and imipenem associated grand mal seizures in allogeneic bone marrow transplantation (BMT). *Annals of Oncology* 1998 9:140.
- 2.4.1.5.** Erdal S, Karacay S, **Turhal NS**. Symptomatic Treatment of Chemotherapy Induced Mucositis. *Anti-Cancer Treatment* 1999 9:259.
- 2.4.1.6.** **Turhal NS**, Ekenel M, Ozgan A, Bekiroglu N. Attitude Toward Genetic Testing for Cancer Risk Assessment in Turkish Society. *European Journal of Gynecological Oncology* 1999 20(Supp): 121-122.
- 2.4.1.7.** **Turhal NS**, Kabakas F, Atalay G, Karamanoglu A. Outpatient Cancer Care in a Turkish University Hospital. *Proceedings of American Society of Clinical Oncology* 1999, 1652.
- 2.4.1.8.** Salepci T, **Turhal NS**. Cisplatin and etoposide in extra pulmonary small cell cancer. *Proceedings of American Society of Clinical Oncology* 2043, 2000.
- 2.4.1.9.** **Turhal NS**, Gurses I, Akbaba P. Neoplastic disease prevalence during 1998-99 in Marmara University hospital in Istanbul Turkey. *Proceedings of American Society of Clinical Oncology* 1773, 2000
- 2.4.1.10.** Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, Buyukunal E, **Turhal S**, Firat D. Vinorelbine, Epirubicin and 5 FU combination in the first line treatment of metastatic breast carcinoma. *Annals of Oncology* 2000 11(4): 137.
- 2.4.1.11.** Abacioglu U, Sengoz M, Atasoy B, **Turhal S**. A pilot study of low dose weekly gemcitabine and concurrent radiation in patients with locally advanced pancreatic cancer. The third annual global oncology young investigators' meeting. 2001.
- 2.4.1.12.** Sengoz M, Caglar H, Abacioglu U, Atasoy B, **Turhal S**, Gulluoglu B. Patient characteristics and treatment results of postoperatively irradiated breast cancer patients. *The Breast Journal* 2001 7(5): 42.
- 2.4.1.13.** Atalay G, Gumus M, Aliustaoglu M, **Turhal NS**. The method of detection and

its relationship with the disease stage in Turkish breast cancer patients. *The Breast Journal* 2001 7(5): 47

2.4.1.14. Dincbas FO, Koca S, Altinel A, Hancilar T, Cavusoglu M, **Turhal S**, Uskent N, Ozguroglu M, Okkan S. Continuous accelerated hyperfractionated radiotherapy (CHART) plus chemotherapy (CT) with vinorelbine (VB) and cisplatinum (CDDP) in locally advanced NSCLC (TOG-011 study). *European Journal of Cancer* 2001 37(6): S53

2.4.1.15. Gumus M, Atalay G, Aliustaoglu M, Guler S, Ekenel M, Karamanoglu A, **Turhal NS**. Attitude toward genetic testing in Turkish society. *European Journal of Cancer* 2001 37(6): S237.

2.4.1.16. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, **Turhal NS**. Outcome of patients after adjuvant treatment in stage B2/C colon cancer in Istanbul. Twelfth International Congress on Anti-Cancer Treatment. Proceeding Book, February 2002: 150.

2.4.1.17. Aliustaoglu M, Gumus M, Atalay G, Sengoz M, Abacıoğlu U, Karamanoglu A, **Turhal NS**. The survival characteristics of the stage IIIB and IV non small cell lung cancer patients in Marmara University Hospital in Istanbul, Turkey. Twelfth International Congress on Anti-Cancer Treatment. Proceeding Book, February 2002: 124.

2.4.1.18. Atalay G, Gumus M, Aliustaoglu M, **Turhal NS**. Predictive factors associated with axillary lymph node metastasis (ALNM) in T1, T2 and T3 breast carcinomas. *European Journal of Cancer* 2002 38(3): S115.

2.4.1.19. Karamanoglu A, Yumuk PF, Gumus M, Aliustaoglu M, Selimen D, Sengoz M, **Turhal NS**. Port needles need not be removed as frequently in infusional cancer chemotherapy, our experience in a university hospital in Istanbul, Turkey. *Bone Marrow Transplantation* 2002 29(2): S275.

2.4.1.20. Gumus M, Aliustaoglu M, Atalay G, Dane F, Caglar H, Sengoz M, **Turhal NS**. The extension of nodal sampling in colorectal cancer patients in Marmara University Hospital, Istanbul. *Proceedings of ASCO Volume 21*, (abstr 2345), 2002: 133b.

2.4.1.21. **Turhal NS**, Efe B, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M. Patient satisfaction in Marmara University outpatient chemotherapy unit in Istanbul. *Proceedings of ASCO Volume 21*, 2002: 252b.

2.4.1.22. Aliustaoglu M, Atalay G, Gumus M, **Turhal NS**. Outcome of adjuvant treatment in elderly Turkish breast cancer patients. *Proceedings of ASCO Volume 21*, 2002: 259b.

2.4.1.23. Dane F, **Turhal NS**, Gumus M, Dede F, Cakaloglu F, Savci D, Gulluoglu B, Kayahan M, Turoglu T. 99m-Tc-MDP scintimammography to assess angiogenesis in patients with untreated breast cancer. *Proceedings of ASCO Volume 21*, 2002: 291b.

2.4.1.24. Aliustaoglu M, Yumuk F, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, Atalay G, Mutlu N, **Turhal NS**. Plasma D-dimer levels in patients with benign and malignant gastric lesions. *Annals of Oncology* 2002 Vol 13 (Supp 5): 190.

2.4.1.25. Atalay G, Gumus M, Aliustaoglu M, Abacıoğlu U, Sengoz M, Gulluoglu B,

Turhal NS. Outcome of Turkish breast cancer patients who received epirubicin based adjuvant chemotherapy. *Annals of Oncology* 2002 Vol 13 (Supp 5):44.

2.4.1.26. Ekenel M, Atalay G, Gumus M, Yumuk F, Aliustaoglu M, Karamanoglu A, **Turhal NS.** Incidence of chemotherapy induced amenorrhea in premenopausal Turkish breast cancer patients. *Fourteenth International Congress on Anti-Cancer Treatment Proceeding Book*, February 2003: 159.

2.4.1.27. Ekenel M, Atalay G, Gumus M, Yumuk F, Aliustaoglu M, Karamanoglu A, **Turhal NS.** Outcome of breast cancer patients after adjuvant therapy in Istanbul, Turkey. *Fourteenth International Congress on Anti-Cancer Treatment Proceeding Book*, February 2003: 160

2.4.1.28. Aydin SZ, Yumuk PF, Ekenel M, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M, **Turhal NS.** The absence of irinotecan associated acute diarrhea with atropine premedication. *Proceeding Book*, 205-206, 14th International Congress on Anti-Cancer Treatment, Paris, France, 1-4 February, 2003.

2.4.1.29. Turhal NS, Gumus M, Ekenel M, Guzet E, Yumuk F, Avery B. Prognostic factors and treatment outcomes of adjuvant breast cancer patients in two locations: Tennessee USA and Istanbul Turkey. *Proceedings of ASCO Volume 22*, 2003: 556.

2.4.1.30. Komurcu S, **Turhal NS,** Altundag K, Atahan L, Savas-Turna H, Manavoglu O, Yavuz AA, Ozkok S, Aliustaoglu M, Altınbas M, Pak Y, Cooper R, Yaylacı M, Demirkan B, Engin K, Ozdemir F. A clinical evaluation of transdermal fentanyl in adults with cancer pain: Phase IV, multicentre trial. *Supportive Care in Cancer* 2003 11(6): A39.

2.4.1.31. Aliustaoglu M, Gumus M, Yumuk F, Ekenel M, Karamanoglu A, Sengoz M, **Turhal NS.** The survival characteristics of the stage IIIB and IV non small cell lung cancer patients in Marmara University hospital in Istanbul, Turkey. *Lung cancer* 2003 Vol 41 Supp:2 S94.

2.4.1.32. Dane F, Iyikesici S, Gumus M, Yumuk PF, Ekenel M, Atalay G, Karamanoglu A, **Turhal NS.** Adjuvant treatment outcome of high risk stage II and III colon cancer patients treated in Marmara University, Istanbul. *Proceeding Book*, 206-207, 15th International Congress on Anti-Cancer Treatment, Paris, France, 9-12 February, 2004 p247.

2.4.1.33. Gunduz F, Yumuk PF, Dane F, Peker O, Ekenel M, Iyikesici S, Atalay G, **Turhal NS.** Mantle cell lymphoma presenting as a breast mass. *Proceeding Book*, 206-207, 15th International Congress on Anti-Cancer Treatment, Paris, France, 9-12 February, 2004 p211.

2.4.1.34. Dane F, Yumuk PF, **Turhal NS,** Ekenel M, Basaran G, İyikesici S, Tecimer C. Folfox4 in metastatic colorectal cancer (MRC) patients who progressed after infusional 5FU/Irinotecan based combination regimens. *Proceedings ASCO Volume 23*, 2004:3729.

2.4.1.35. Aliustaoglu M, Gumus M, Midi A, Celikel C. A, Ekenel M, Yumuk PF, Basaran G, **Turhal NS.** Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients tumors. *Proceedings ASCO Volume 23*, 2004:3731

- 2.4.1.36.** Cabuk D, Yumuk PF, Abacioglu U, Demir G, Dane F, Gumus M, Ozguroglu M, Ekenel M, Basaran G, **Turhal NS**. Is the incidence of anal cancers different in Moslem societies. Proceedings ASCO Volume 23, 2004:4233
- 2.4.1.37.** Abacioglu U, Yumuk PF, Caglar H, Sengoz M, **Turhal NS**. Results of concurrent chemoradiotherapy (CRT) with low dose weekly gemcitabine (G) in stage III non-small cell lung cancer (NSCLC). Proceedings ASCO Volume 23, 2004:7318
- 2.4.1.38.** Yumuk PF, **Turhal NS**, Gumus M, Hatabay NF, Turken O, Ozkan A, T. Selepci, Aliustaoglu M, Ekenel M, Ahiskali R. Paclitaxel (P) (day 1 and 8) and carboplatin (C) given on every 3 weeks in advanced (stage III-IV) non-small cell lung cancer (NSCLC). Proceedings ASCO Volume 23, 2004:7321
- 2.4.1.39.** Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Ekenel M, Basaran G, Dane F, Kaya H, Barisik N, **Turhal NS**; Human papilloma virus: Is it a new etiological factor in breast cancer?. Proceedings ASCO Volume 23, 2004:9635
- 2.4.1.40.** **Turhal NS**, Popov I. Colorectal cancer care in Balkans. Proceedings of Balkan Union of Oncology Educational Book 2004 C-109
- 2.4.1.41.** Basaran GA, Ekenel M, Demirkalem P, Cakir T, Gulluoglu B, Gumus M, Dane F, İyikesici S, Yumuk F, **Turhal S**. Clinical outcome of breast cancer patients with pT1N0M0 disease. Annals of Oncology 2004 15(3):257P, iii68.
- 2.4.1.42.** Dane F, **Turhal NS**, İyikesici S, Gumus M, Yumuk PF, Basaran G, Ekenel M, Avery B. Clinical features and adjuvant treatment outcomes of colon cancer in two outpatient populations of Knoxville Tennessee and İstanbul Turkey. Annals of Oncology 2004 15(3): 355P, iii95
- 2.4.1.43.** İyikesici S, **Turhal NS**, Yumuk PF, Dane F, Gumus M, Basaran G, Ekenel M, Avery B. Treatment outcomes in non-small cell lung cancer patients: Comparison between Marmara University, İstanbul Turkey and Knoxville Tennessee. Annals of Oncology 2004 15(3): p741, iii195.
- 2.4.1.44.** Yumuk PF, **Turhal NS**, Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T, Aliustaoglu M, Ahiskali R. Results of Paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer. BMC Cancer. 2005 Jan 25;5:10.
- 2.4.1.45.** Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel M, Basaran G, **Turhal NS**, Does the incidence of anal canal cancers differ in Moslem societies? International Journal of Colorectal Disease 2005 20:76
- 2.4.1.46.** İyikesici MS, Kefeli U, Basaran G, Dane F, Ekenel M, Yumuk PF, **Turhal NS**, The prognostic impact of body mass index (BMI) in early breast cancer (BC) patient (pts) Proceedings ASCO Volume 23, 2005:882

- 2.4.1.47.** Basaran G, Dane F, Iyikesici S, Ekenel M, Yumuk PF, **Turhal NS**, Clinical and pathological characteristics of early breast cancer (EBC) patients <35 years old. Proceedings ASCO Volume 23, 2005:887
- 2.4.1.48.** Ekenel M, Basaran G, Dane F, Iyikesici S, Yumuk PF, **Turhal NS**, outcome of adjuvant treatment in elderly Turkish breast cancer patients. Proceedings ASCO Volume 23, 2005:896
- 2.4.1.49.** Cabuk D, Basaran G, Yumuk PF, Celikel C, Dane F, Iyikesici MS, Ekenel M, **Turhal NS**, VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival. Proceedings ASCO Volume 23, 2005:4040
- 2.4.1.50.** Gumus M, Palak B, Iyikesici S, Yumuk PF, Seker M, Topal A, Dane F, Salepci T, Yayla A, **Turhal NS**, Outcome of elderly patients with advanced non-small cell lung cancer. Proceedings ASCO Volume 23, 2005:7345
- 2.4.1.51.** **Turhal NS**, Popov I. Colorectal cancer care in the Balkan countries. Journal of Balkan Union of Oncology Volume 10 No: 2, April-June 2005 189-193
- 2.4.1.52.** Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, **Turhal NS**, What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery? Tumori. 2005 Mar-Apr;91(2): 168-72
- 2.4.1.53.** Abacioglu U, Yumuk PF, Caglar H, Sengoz M, **Turhal NS**, Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer, 2005 Jul 6;5:71
- 2.4.1.54.** Yumuk PF, **Turhal NS**, Ahiskali R, Gumus M, Hatabay N, Turken O, Ozkan A, Salepci T, Aliustaoglu M. P53 or Her2/neu as prognostic factors in advanced non-small-cell lung cancer treated with paclitaxel. 11th World Conference on Lung Cancer, Barcelona, Spain. 3-6 July 2005.
- 2.4.1.55.** Iyikesici MS, Yumuk PF, Dane F, Ekenel M, Basaran G, **Turhal NS**, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital. 11th World Conference on Lung Cancer, Barcelona, Spain. 3-6 July 2005.
- 2.4.1.56.** Iyikesici M, Yumuk PF, Dane F, Ekenel M, Basaran G, **Turhal NS**, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey. Abstract of the 11th World Conference on Lung Cancer, Elsevier Volume 49 Supp 2, 2005: S249
- 2.4.1.57.** Yumuk PF, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Dane F, Iyikesici S, Basaran G, **NS Turhal**, "The impact of body mass index on cancer: A Hospital-based study," *14th European Congress on obesity, Blackwell Publishing*, Volume 6, Supplement 1, Page 82 (Abstract 256), Athens, 2005.
- 2.4.1.58.** Onol FF, Tandr Y, Kotiloglu E, Bayramicli M, **Turhal NS**, Turkeri LN. Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention. Part 1: Eur Urol 2006 Feb;49(2): 406-7

- 2.4.1.59.** Onol FF, Tandr Y, Kotiloglu E, Bayramicli M, **Turhal NS**, Turkeri LN. Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention. Part 2: Eur Urol. 2006 Mar; 49(3):578-80.
- 2.4.1.60.** Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S, Mayadagli A, **Turhal NS**, Sengoz M. Tolerability assessment of urasil-tegafur (UFT)/folinic acid (FA) as concurrent chemoradiation (CRT) in adjuvant rectal cancer treatment. Marmara University School of Medicine, Istanbul, Turkey; Lutfi Kirdar Kartal State Hospital, Istanbul, Turkey. Proceedings ASCO Volume 24 2006:13559
- 2.4.1.61.** Dane F, Gumus M, Iyikesici MS, Yumuk PF, Basaran G, Atasoy BM, Abacioglu U, Cabuk D, Teomete M, **Turhal NS**, Outcome of rectal carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital, Istanbul, Turkey. Proceedings ASCO Volume 24 2006:13584
- 2.4.1.62.** Yalcin B, Aydin F, Zengin N, Ilhan M, Isikdogan A, Aykan F, Demir G, Celik I, **Turhal NS**, Icli F, Akbulut H. The clinicopathological and socioeconomic features of patients with gastric cancer in Turkey (Turkish Oncology Group). Proceedings ASCO Volume 24 2006: 20098
- 2.4.1.63.** Kefeli U, Karamanoglu A, Dane F, Yumuk PF, Iyikesici MS, Basaran G, **Turhal NS**. Prolonged interval in Prophylactic Heparin Flushing for Maintenance Subcutaneous Implanted Port Care in Patients with Cancer. 17th International Congress on Anti-Cancer Treatment, Abstract Book Page 348, 30th January-2nd February 2006, Paris, France
- 2.4.1.64.** Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, **Turhal NS**. HPV DNA frequency and subset analysis in human breast cancer patients normal and tumoral tissue samples. Journal of Experimental and Clinical Cancer Research (in press, December 2006)
- 2.4.1.65.** Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk FP, Akgun Z, Ozden S, Mayadagli A, **Turhal NS**, M Sengoz, "Concurrent administration of urasil-tegafur and folinic acid with radiation for locally advanced rectum cancer: tolerability and quality of life assessments," *25th ESTRO Annual Meeting, Leipzig, Radiother Oncol.*, Vol. 81 (Suppl. 1), S234, Elsevier, Ireland, 2006.
- 2.4.1.66.** Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S, Mayadagli A, **Turhal NS**, Sengoz M. Concomitant administration of uracil-tegafur (UFT) and folinic acid (FA) during irradiation for locally advanced rectal cancer: tolerability assessment. 6th Congress Balkan Union of Oncology, 13-16 September 2006, Sofia, Bulgaria, 58:OP80,
- 2.4.1.67.** Dane F, Gumus M, Iyikesici S, Basaran G, Ozturk A, Atasoy BM, Abacioglu U, Cabuk D, Teomete M, **Turhal NS**, Division of Medical Oncology, Marmara University Hospital, Istanbul, Turkey. Outcome of rectal carcinoma patients receiving adjuvant chemoradiotherapy. 6th Congress Balkan Union of Oncology, 13-16 September 2006, Sofia, Bulgaria, 61:PP93.

2.4.1.68. Dane F, Yumuk PF, Gumus M, Iyikesici S, Tufan A, Basaran G, Cabuk D, Ozturk A, Erdem R, Teomete M, **Turhal NS**, Dept. Of Internal Medicine Division of Oncology, Marmara University Hospital, Istanbul, Turkey. Outcome of unresectable locally advanced and/or metastatic colorectal cancer patients receiving systemic chemotherapy. 6th Congress Balkan Union of Oncology, 13-16 September 2006, Sofia, Bulgaria, 64:PP107.

2.4.1.69. Turhal NS, Dept. Of Internal Medicine Division of Oncology, Marmara University Hospital, Istanbul, Turkey. Integration of Balkan Oncology in International Study Groups: the University of Marmara Experience. 6th Congress Balkan Union of Oncology, 13-16 September 2006, Sofia, Bulgaria, 109:OP251.

2.4.1.70. Cabuk D, Basaran G, Iyikesici S, Ekenel M, Dane F, Teomete M, Gumus M, Aliustaoglu M, Yumuk PF, **Turhal NS**, Marmara University Hospital, Medical Oncology, Istanbul, Turkey. Outcome of adjuvant treatment in Turkish Breast Cancer (BC) patients (PTS): single institution experience. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/302

2.4.1.71. Yumuk PF, Gumus M, Kaya H, Alam K, Dane F, Gulluoglu B, Salepci T, Barisik N, Basaran G, **Turhal NS**. Association Between Presence of HPV DNA and P53 in Breast Cancer Patients. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/311

2.4.1.72. Basaran G, Cabuk D, Caglar H, Iyikesici S, Tebessum C, Gulluoglu B, Kaya H, Dane F, Yumuk PF, **Turhal NS**. Stage I (T1N0M0) Breast Cancer (BC): Pathological Characteristics and Clinical Outcome. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/321

2.4.1.73. Dane F, Yumuk PF, Gumus M, Iyikesici S, Tufan A, Basaran G, Cabuk D, Teomete M, **Turhal NS**, Marmara University Hospital Department of Oncology Istanbul, Turkey. Ourcome of metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University Hospital. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/378

2.4.1.74. Dane F, Gumus M, Yumuk PF, Iyikesici S, Ozturk A, Basaran G, Caglar H, Cabuk D, Teomete M, **Turhal NS**, Marmara University Hospital Department of Oncology Istanbul, Turkey. Ourcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University Hospital. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/384.

2.4.1.75. Atasoy B, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S, Mayadagli A, **Turhal NS**, Sengoz M. Adjuvant comcomittant administration of Urasil-Tegafur (UFT) and folinic acid (FA) during irradiation for locally advanced rectum cancer: Tolerability assessment. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/401

2.4.1.76. Teomete M, Yumuk PF, Iyikesici S, Dane F, Basaran G, Cabuk D, Caglar H, Abacioglu U, **Turhal NS**. Outcome of patients with stage III and IV non-small cell lung

cancer in Marmara University Hospital, Istanbul, Turkey. *Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey.* Volume 17, Supp, 9/757P

2.4.1.77. Dane F, Topaloglu N, Abul Y, Yumuk PF, **Turhal NS**, Ceyhan B, Celikel T, Caglar H, Basaran G, Ahiskali R. Interstitial pneumonitis associated with Docetaxel administration. *Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey.* Volume 17, Supp, 9/1069

2.4.1.78. Demir G, Zengin N, Yildiz O, Dogusoy G, Aykan F, Er O, Isikdogan A, **Turhal NS**, Yilmaz U, Yalcin S. The role of lymph nodes on disease free survival in operated gastric cancer (Turkish Oncology Group Study). *Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey.* Volume 17, Supp, 9/1100

2.4.1.79. Demir G, Zengin N, Yildiz O, Ozdamar S, Aykan F, Er O, Ilhan M, **Turhal NS**, Yilmaz U, Yalcin S. Clinical profile of gastric cancer in Turkey: Factors effecting disease free survival and relapse (Turkish Oncology Group Study). *Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey.* Volume 17, Supp, 9/1139

2.4.1.80. Basaran G, Guney N, Saip P, Iyikesici S, Kaya H, Yazıcı H, **Turhal NS**. Serum extracellular domain (ECD) levels, pAkt and MAKP expressions as potential markers for response to trastuzumab base therapy in metastatic breast cancer patients: A Turkish Oncology Group Study. *Ann Oncol.* 2006 Sept; 17 (Supp 9): ix69–ix92, Abstract 230, Istanbul, 2006.

2.4.1.81. Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli A, Basaran G, **Turhal NS**, Sengoz M. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer. *Journal of BUON* 12: 203-208, 2007

2.4.1.82. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar H, Abacioglu U, Basaran G, **Turhal NS**, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer. *Journal of Thoracic Oncology*, Volume 2, Number 8, Supplement 4, August 2007.

2.4.1.83. M. Gumus, F. Dane, S. Kaya, M. A. Ozturk, P. F. Yumuk, B. M. Atasoy, G. Basaran, T. Salepci, M. Yaylaci, **N. S. Turhal**. The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 15159.

2.4.1.84. F. Dane, M. Gumus, A. Ozturk, F. Yumuk, S. Iyikesici, G. Basaran, D. Cabuk, M. Teomete, **N. S. Turhal**. Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14588

2.4.1.85. G. Atalay Basaran, D. Cabuk, F. Dane, M. Teomete, S. Iyikesici, E. Meltem, B. Gulluoglu, H. Kaya, U. Abacioglu, F. Yumuk, **S. Turhal**. Clinical outcome of node-negative (NN) breast cancer (BC) patients. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 11102

2.4.1.86. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar H, Abacioglu U, Basaran G, **Turhal NS**, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer. *Journal of Thoracic Oncology*, Volume 2, Number 8, Supplement 4, August 2007.

2.4.1.87. Basaran G, Cabuk D, Teomete M, Gulluoglu B, Kaya H, Dane F, Yumuk PF, **Turhal NS**, Benefit from adjuvant anthracyclines according to hormone receptor status. Annual Meeting ASCO 2008: 11513

2.4.1.88. Turhal NS, Ulus C, Sari S, Senturk N, Bingol D. Cancer-related knowledge in relatives of cancer patients and general public in İstanbul, Turkey, Annual Meeting ASCO 2008: 20650

2.4.1.89. F Dane, M Gumus, MA Ozturk, D. Cabuk, MB Atasoy, PF Yumuk, G Basaran, MS Iyikesici, M Teomete, U Abacioglu, **NS Turhal**. Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience. Annual Meeting ASCO 2008: 15103

2.4.1.90. D Cabuk, G Basaran, H Kaya, B Gulluoglu, M Teomete, F Dane, PF Yumuk, **NS Turhal**. Clinical outcome of triple-negative (TN) breast cancer (BC). Annual Meeting ASCO 2008: 11526

2.4.1.91. Dane F, Gumus M, Yaman E, Ozturk MA, Sevinc A, Atasoy BM, Cabuk D, Iyikesici S, Yumuk PF, Basaran G, Abacioglu U, Teomete M, **NS Turhal**, "Demographical Survival and Prognostic Features of Resected Rectal Cancer in Turkish Patients Population," *18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists*, İstanbul, Hepato-gastroenterology, Vol. 55, (Suppl. 1), OP70, A28, H.G.E. Update Medical Publishing, Greece, 2008.

2.4.1.92. Cabuk D., Basaran G, Teomete M, Dane F, Yumuk PF, **Turhal NS**, "Clinical/pathological characteristics of breast cancer (BC) patients (pts) with triple-negative (TN) tumors," *7th Congress of Balkan Union of Oncology (BUON)*, Proceedings, OP-53, İzmir, 2008.

2.4.1.93. Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, **Turhal NS**, "Platinum plus vinorelbine (VNR) on days 1 and 8 in advanced non-small cell lung Cancer: Single center results," *7th Congress of Balkan Union of Oncology (BUON)*, Proceedings, OP-72, İzmir, 2008.

2.4.1.94. Dane F, Gumus M, Ozturk A, Cabuk D, Basaran G, **Turhal NS**, "Demographics, survival and prognostic features of resected colon Cancer in Turkish patients population," *7th Congress of Balkan Union of Oncology (BUON)*, Proceedings, OP-92, İzmir, 2008.

- 2.4.1.95.** Dane F, Ozturk A, Gumus M, Yumuk F, Basaran G, **Turhal NS**, "Survival and prognostic features of stage II and III Rectal Cancer (RC) in Turkish patients population," *7th Congress of Balkan Union of Oncology (BUON)*, Proceedings, OP-93, İzmir, 2008.
- 2.4.1.96.** Dane F, Gumus M, Cabuk D, Teomete, M, Yumuk PF, **Turhal NS**, "Prognostic factors and treatment outcomes in patients with metastatic colorectal cancer (CRC)," *7th Congress of Balkan Union of Oncology (BUON)*, Proceedings, OP-94, İzmir, 2008.
- 2.4.1.97.** Civen H, Dede F, Dane F, Ustaoglu MA, **Turhal NS**, Turoglu H, Inanir S, "Does the standard test parameters for C-14 urea breath test really work in partially gastrectomised patients with gastric cancer," *Annual Congress of the European Association of Nuclear Medicine, Eur. J. Nucl. Med.*, 35, S238, Münih, 2008.
- 2.4.1.99.** Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, **Turhal NS**, Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC). 2009 ASCO Annual Meeting, *J Clin Oncol* 27, 2009 (suppl; abstr e19055),
- 2.4.1.100.** **Turhal NS**, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight gain after adjuvant treatment in breast cancer patients in Istanbul, Turkey. 2009 ASCO Annual Meeting, *J Clin Oncol* 27, 2009, (suppl; abstr e11620),
- 2.4.1.101.** Abali H, Ata A, **Turhal NS**, Ozdogan M, Seyrek E, Erman M, Celik I. Frequency of co-morbid illnesses in cancer patients in Turkey. 2009 ASCO Annual Meeting, *J Clin Oncol* 27, 2009, (suppl; abstr e20717),
- 2.4.1.102.** Kefeli U, Yumuk PF, Ceyhan B, Dane F, Eroglu B, Cabuk D, Basaran G, Teomete M, **Turhal NS**, Pulmonary toxicity in patients receiving docetaxel chemotherapy. 2009 ASCO Annual Meeting, *J Clin Oncol* 27, 2009, (suppl; abstr e13532),
- 2.4.1.101.** Ustaalioglu BB, Gumus M, Bilici A, Seker M, Dane F, Salepci T, Salman T, Aliustaoglu M, Gezen C, Yaylaci M, **Turhal NS**, Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience. *Med. Oncol*, 2009 Jun 2.
- 2.4.1.102.** Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici M, Basaran G, **Turhal NS**, Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. *Eur J Cancer Care (Engl)*, 2009 Mar; 18(2), 191-4.
- 2.4.1.103.** Kuscu MK, Dural U, Onen P, Yasa Y, Yayla M, Basaran G, **Turhal NS**, Bekiroglu N. The association between individual attachment patterns, the perceived social support, and the psychological well-being of Turkish informal caregivers. *Psychooncology*, 2009 Jan 12.
- 2.4.1.104.** Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete M, **Turhal NS**. *A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: The importance of second opinion.* *J BUON*, 2009 Apr-Jun;14(2):309-11.

- 2.4.1.105.** Gumus M, Basak O, Ustaalioglu MG, Kiziltan E, Bilici A, Seker M, Erkol B, Salepci T, Mayadagli A, **Turhal NS.** *Factors that Affect Patients' Decision-Making about Mastectomy or Breast Conserving Surgery, and the Psychological Effect of this Choice on Breast Cancer Patients.* Breast Care 2010;5:164–168
- 2.4.1.106.** Turhal NS, Dane F, Seber S, Korkmaz T, Cabuk D, Basaran G, Yumuk F, Caglar H, Atasoy B. “Challenges in applicability of Standard treatment for head and neck cancer patients in Istanbul”. Euroasian Congress on Head & Neck Oncology, Minsk, Republic of Belarus, 16-19 July 2009, Вестник РОНЦ им. Н. Н. Блоина, Proceedings, 20(2), 2009: 116.
- 2.4.1.107.** Dane F, Yumuk PF, Başaran G, Gündüz F, Peker Ö, **Turhal NS,** *A Case of Primary Breast Mantle Cell Lymphoma with Atypical Relapse Patterns and Review of the Literature* Journal of BUON Vol: 16 No: 2, 2011
- 2.4.1.108.** **Turhal NS,** Bas E, Er O, Aliustaoglu M, Seber S, Dane F, Korkmaz T, Soyuer I, Ozkara S, Celikel C. *ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study.* Journal of BUON 15: 794-796, 2010
- 2.4.1.109.** **Turhal NS.** Dane F, Sınav H, Yalçın N, Khorshidi Z, Yalçın ZZ. *Anxiety and depression in Turkish breast cancer patients.* Journal of BUON 15: 720-725, 2010
- 2.4.1.110.** Korkmaz T, Seber S, **Turhal NS.** *Primary melanoma of the gallbladder.* Letter 802
- 2.4.1.111.** Cabuk D, Basaran G, Korkmaz T, Seber S, Dane F, Telli F, Yumuk F, **Turhal NS.** *Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities.* European Breast Cancer Conference 7, 24-30 March 2010 Barcelona. Eur J Cancer Supplements, Vol . 8, No 3, p205, Poster 498 (2010)
- 2.4.1.112.** **Turhal NS,** Basaran G, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. *Weight Gain after Adjuvant Chemotherapy in Early Breast Cancer Patients in Istanbul Turkey.* American Society of Clinical Oncology 2010 Annual Meeting June 4-8 2010
- 2.4.1.113.** Basaran G, Cabuk D, Korkmaz T, Kocar M, Telli F, Dane F, Yumuk F, **Turhal NS.** *Clinical, pathological factors predicting early relapse in hormone receptor early breast cancer.* BUON Congress 2010, **Best Abstracts Presented at BUON Congress 2010,** Proceedings Book, 8-11 September 2010, Sibiu, Romania. BA 28, page 13
- 2.4.1.114.** **Turhal NS,** Dane F, Seber S, Korkmaz T, Yumuk F, Kanitez M, Telli F, Kocar M, Basaran G. Tolerability of anthracyclines in Turkish breast cancer patients. BUON Congress 2010, Proceedings Book, 8-11 September 2010, Sibiu, Romania. Oral presentation OP-32, page 14
- 2.4.1.115.** Ozturk MA, Dane F, Karagoz S, Tural D, Demirelli F, Basaran G, Buyukunal E, Mandel NM, Ç Erdamar S, Turna H, Seber S, **Turhal NS,** Serdengeçti S. *The prognostic value of perineural invasion in patients with early stage colon cancer.* BUON Congress 2010, **Best Abstracts Presented at BUON Congress 2010,** Proceedings Book, 8-11 September 2010, Sibiu, Romania. BA 65, page 23
- 2.4.1.116.** Basaran G, Cabuk D, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, Yumuk PF, **Turhal NS.** *Clinical outcome of breast cancer patients with N3a*

(≥ 10 positive lymph nodes) disease: has it changed over years? *Med Oncol*. 2010 Apr 14. [Epub ahead of print] DOI 10.1007/s12032-010-9516-1.

2.4.1.117. Dane F, Yumuk PF, Gunduz F, Peker O, Basaran G, **Turhal NS**. *A case of primary breast mantle cell lymphoma with atypical relapse patterns and review of the literature*. *J BUON*, 16(2) (2011). (yayımda) (**Derleme**)

2.4.1.118. Korkmaz T, Seber S, Basaran G, Yumuk PF, **Turhal NS**, Dane F, Telli F, Kocar M. *5-Flourouracil-Induced Encephalopathy in Parkinson's disease*. *Inter J Hemat Oncol* (yayımda) (**Derleme**)

National Meeting Abstracts:

- 2.4.2.1.** Dincbas FO, Koca S, Altinel A, Hancılar T, Cavusoglu M, **Turhal S**, Uskent N, Ozguroglu M, Okkan S. “Evre III küçük hücreli dışı akciğer kanserinde (KHDAK) aralıksız hızlandırılmış hiperfraksiyone radyoterapi (CHART) ve kemoterapi çalışması (TOG-011 çalışması – Erken sonuçlar)” *Bildiri Özetleri, XIV. Ulusal Kanser Kongresi* (Uluslararası katılımlı). SB-06 s: 62. İstanbul, 2001
- 2.4.2.2.** Abacıoğlu U, Sengoz M, Çağlar H, Gumus M, Atalay G, **Turhal S**. “Rektum ve sigmoid kanserlerinde adjuvan kemoradyoterapi sonuçları” *Bildiri Özetleri, XIV. Ulusal Kanser Kongresi* (Uluslararası katılımlı), SB-07 s: 64. İstanbul, 2001
- 2.4.2.3.** Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, Buyukunal E, **Turhal S**, Firat D. “Metastatik meme kanserinin birinci basamak tedavisinde Vinorelbine Epirubisin 5-Fluorourasil kombinasyonunu” *Bildiri Özetleri, XIV. Ulusal Kanser Kongresi* (Uluslararası katılımlı). SB-09 s: 69. İstanbul, 2001
- 2.4.2.4.** Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Dane F, **Turhal NS**. “Marmara Üniversitesi Hastanesi’nde izlenen evre II ve evre III kolon kanserli hastaların değerlendirilmesi” *Bildiri Özetleri, XIV. Ulusal Kanser Kongresi* (Uluslararası katılımlı). SB-14 s: 84. İstanbul, 2001
- 2.4.2.5.** Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, **Turhal NS**. “Marmara Üniversitesi Hastanesi’nde izlenen evre IV kolon kanserli hastaların değerlendirilmesi” *Bildiri Özetleri, XIV. Ulusal Kanser Kongresi* (Uluslararası katılımlı). SB-14 s: 85. İstanbul, 2001
- 2.4.2.6.** Aliustaoglu M, Atalay G, Gumus M, Karamanoglu A, **Turhal NS**. “Marmara Üniversitesi Hastanesi’nde izlenen evre III B-IV küçük hücreli dışı akciğer kanserli hastaların sürvi karakteristiklerinin değerlendirilmesi” *Bildiri Özetleri, XIV. Ulusal Kanser Kongresi* (Uluslararası katılımlı). PO-05 s: 187. İstanbul, 2001
- 2.4.2.7.** Dane F, **Turhal NS**, Gumus M, Dede F, Sengoz M, Yumuk F, Turoglu T. Tc-99m MDP scintimammography in the detection of breast lesions. *Turkish Journal of Nuclear Medicine* Volume 11(1), 2002: 47.
- 2.4.2.8.** Dane F, **Turhal NS**, Gumus M, Dede F, Cakalagaoglu F, Yumuk F, Turoglu T. Correlation between Tc-99m MDP uptake and prognostic factors in breast cancer. *Turkish Journal of Nuclear Medicine* Volume 11, 2002: 11
- 2.4.2.9.** Komurcu S, **Turhal NS**, Altundag K, Atahan L, Savas-Turna H, Manavoglu O, Yavuz AA, Ozkok S, Aliustaoglu M, Altınbas M. “A clinical evaluation of transdermal fentanyl in adults with cancer pain: Phase IV, multicentre trial”. *Program ve Bildiri Özet Kitabı XV. Ulusal Kanser Kongresi* , , P079 ref 0381 s:48. Antalya, 2003.
- 2.4.2.10.** Aliustaoglu, M., **Turhal, S.**, Ekenel, M., Gümüş, M. ve Yumuk PF, “Evre III over kanserinde kemoterapi sonuçlarımız”, *Program ve Bildiri Özet Kitabı, XV. Ulusal Kanser Kongresi*, P290, Antalya, 2003.

2.4.2.11. Gümüş, M., Dane, F., Aliustaoğlu, M., Yumuk, P.F., Ekenel, M., Selepçi, T., Barışık, N. ve **Turhal NS**, “Meme kanserli hastalarda normal ve tümoral doku örneklerinde human papillomavirus (HPV) DNA sıklığı ve HPV tip tayini”, *Kurs ve bildiri özet kitabı, VII. Ulusal Meme Hastalıkları Kongresi*, s: 44, Antalya, 2003.

2.4.2.12. Ekenel, M., Başaran, G., Gümüş, M., Aliustaoğlu, M., Dane F., Yumuk, P.F. ve **NS Turhal**, “Premenopozal meme kanseri hastalarında kemoterapiye bağlı amenore insidansı ve prognostic rolü”, *Kurs ve Bildiri Özet Kitabı, VII. Ulusal Meme Hastalıkları Kongresi*, P82, Antalya, 2003.

2.4.2.13. Abacıoğlu, U., Odabaş, Ö.F., Tezcanlı, E., Çağlar, H., Yumuk, P.F., Şengöz, M. ve **Turhal S**, “Kolonorektal Kanserli Hastaların Yaşam Kalitesini Değerlendirmede EORTC Kolorektal Kanser Modülü QLQ-CR38’in Türkçe Çevirisi ve Pilot-Test Çalışması”, *Bildiri Özet Kitabı, VI. Ulusal Radyasyon Onkolojisi Kongresi*, P45, Antalya, 2004.

2.4.2.14. Çağlar, H., Abacıoğlu, U., Tezcanlı, E., Yumuk, F., **Turhal, S.** ve M. Şengöz, “Lokal ileri evre pankreas kanserli hastalarda radyoterapi ve eş zamanlı gemsitabin tedavisinin toksisite ve sağkalım sonuçları”, *Bildiri Özet Kitabı, VI. Ulusal Radyasyon Onkolojisi Kongresi*, P48, Antalya, 2004.

2.4.2.15. Yumuk PF, İyikesici S, Gumus M, Aliustaoğlu M, Dane F, Başaran G, Ekenel M, Abacıoğlu U, **Turhal NS**. “Kemoterapi verilen lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri hastalarının sağ kalım ve prognostik açıdan değerlendirilmesi” *Final Program ve Bildiri Özet Kitabı, I. Ulusal Torasik Onkoloji Kongresi*, S79 Antalya, 2004.

2.4.2.16. Yumuk PF, Gümüş M, Dane F, Kaya H, Alam K, İyikesici MS, Güllüoğlu B, Ekenel M, Atalay G, **Turhal NS**, “Meme kanseri hastalarında HPV-DNA ampfilikasyonu ve P53 ekspresyonunun prognostik değeri” *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 873, Antalya, 2005.

2.4.2.17. Yalçın B, Aydın F, Zengin N, İlhan M, Demir G, Bozcuk H, Çelik İ, **Turhal NS**, İçli F, Işıkdöğün A, “Türkiye’de mide kanserli hastaların klinik patolojik özellikleri: Çok merkezli retrospektif çalışma (Türk Onkoloji Grubu)” *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 601, Antalya, 2005.

2.4.2.18. Akgün Z, Çetin İ, Karauç, Çağlar H, Abacıoğlu U, Dane F, Yumuk PF, Şengöz M, **Turhal NS**, “Mide adenokarsinomlarında cerrahi rezeksiyon sonrasında adjuvan kemoradyoterapi sonuçlarımız” *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 708, Antalya, 2005.

2.4.2.19. Çetin İ, Akgün Z, Abacıoğlu U, Şengöz M, Yumuk PF, **Turhal NS**, “Lokal ileri evre özafagus kanserli hastalarda primer kemoradyoterapi sonuçları” *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 822, Antalya, 2005.

2.4.2.20. Çetin İ, Akgün Z, Çağlar H, Tezcanlı E, Abacıoğlu U, Şengöz M, Yumuk PF, **Turhal NS**, Türkeri L, “Mesane tümörlü hastaların kemoradyoterapi sonuçları” *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 806, Antalya, 2005.

2.4.2.21. İyikesici MS, Yumuk PF, Dane F, Başaran G, Ekenel M, Abacıoğlu U, Şengöz M, **Turhal NS**, “Marmara Üniversitesi Hastanesindeki Evre III ve IV küçük hücreli dışı akciğer kanserli hastaların sonuçları” *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 805, Antalya, 2005.

2.4.2.22. **Turhal NS**, Yumuk PF, İyikesici MS, Dane F, Başaran G, Ekenel M, Avery B, “Knoxville, Tennessee, USA’da evre III ve IV küçük hücreli dışı akciğer kanserli hastaların sonuçları. *Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi*, Ref 812, Antalya, 2005.

2.4.2.23. Cabuk D, Basaran G, Yumuk PF, Celikel C, Dane F, İyikesici MS, Ekenel M, **Turhal NS**, “Mide kanserinde VEGF, HIF- Alfa, CD34 Ekspresyonu ve bu faktörlerin prognostik önemi”. *Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi*, SB 03, Antalya, 2006.

2.4.2.24. Komurcu S, **Turhal NS**, Altundag K, Atahan L, Turna H, Manavoglu O, Yavuz A, Ozkok S, “Transdermal fentanilin kanser ağrısı olan hastalarda etkinliğinin ve güvenliğinin değerlendirilmesi: FAZ IV, TOG destek tedaviler çalışma grubu”, *Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi*, SB 21, Antalya, 2006.

2.4.2.25. Dane F, Yumuk PF, İyikesici MS, Gumus M, Tufan A, Basaran G, Teomete M, **Turhal NS**, “Palyatif kemoterapi alan metastatik kolorektal kanser hastalarının sağ kalım sonuçları” *Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi*, SB 42, Antalya, 2006.

2.4.2.26. Dane F, Gumus M, İyikesici MS, Yumuk PF, Basaran G, Atasoy B, Abacıoğlu U, **Turhal NS**, “Adjuvan kemoradyoterapi verilen evre II/III rektum kanseri hastalarının sağ kalım ve prognostik açıdan değerlendirilmesi”, *Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi*, SB 45, Antalya, 2006.

2.4.2.27. Atasoy B, Abacıoğlu U, Ozgen Z, Dane F, Yumuk PF, Mayadağlı A, **Turhal NS**, Sengoz M, “Rektum kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı Tegafur-Urasil (UFT) / Folinik Asit (FA) uygulaması: Tolerabilite değerlendirmesi” *Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi*, SB 46, Antalya, 2006.

2.4.2.28. Atasoy BM, Abacıoğlu U, Özgen Z, Dane F, Yumuk PF., Mayadağlı A, **Turhal NS** ve M. Şengöz, “Rektum Kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı Tegafur-Urasil (UFT)/Folinik asit (FA) uygulanması: Tolerabilite Değerlendirilmesi,” *VII. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı*, S13, Fethiye, 2006

2.4.2.29. Dane F, Gumus M, İyikesici MS, Yumuk PF, Ozturk A, Basaran G, Cabuk D, **Turhal NS**, “Adjuvan kemoterapi alan kolon kanseri hastalarının sağ kalım ve prognostik açıdan değerlendirilmesi”, *Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi*, P 066, Antalya, 2006.

2.4.2.30. Öztürk A, Dane F, Tecimer T, Atasoy B, Çabuk D, Yumuk PF, Başaran G, Teomete M, **Turhal NS**. “Onkoloji Kliniğine Refere edilen Selim Bir Lenf Adenopati Nedeni: Kikuchi-Fujimoto Hastalığı” *4. Ulusal Tıbbi Onkoloji Kongresi Özet Kitabı*” B 62, Antalya, 5-9 Eylül 2007.

2.4.2.31. Dane F, Gumus M, Ozturk MA, Atasoy BM, Iyikesici S, Yumuk PF, Basaran G, Abacioğlu U, Cabuk DO, Teomete M, **Turhal NS.** Rektum kanseri olgularının klinik özellikleri ve adjuvant kemoradyoterapi sonuçları: Tek merkez tecrübesi. Tıbbi Onkoloji Kongresi Antalya. 26-30 Mart 2008.

2.4.2.32. Öztürk A, Dane F, Tecimer T, Atasoy B, Çabuk D, Yumuk PF, Başaran G, Teomete M, **Turhal NS.** “Onkoloji Kliniğine Refere edilen Selim Bir Lenf Adenopati Nedeni: Kikuchi-Fujimoto Hastalığı” *4. Ulusal Tıbbi Onkoloji Kongresi Özet Kitabı*” B 62, Antalya, 5-9 Eylül 2007.

2.4.2.33. Gümüş M, Dane F, Kaya S, Öztürk MA, Yumuk PF, Atasoy BM, Başaran G, Salepçi T, Yaylacı M, ve **Turhal NS,** “Mide Kanserinin Adjuvan Tedavisinde Kemoradyoterapinin Etkinliği,” *17.Ulusal Kanser Kongresi, Bildiri Özet Kitabı,* Ref No: 774 Antalya, 2007.

2.4.2.34. Yamaç D, **Turhal NS,** Karaca B, Coşkun HŞ, Kömürcü Ş, Yavuzşen T, Dane F, Yaman E, Nalça M, ve M. Akmansu, “Kanser Tanısını Söyleme Yöntemimizi Sorgulama,” *2.Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı,* SB29 (Sözlü Bildiri), Antalya, 2008.

2.4.2.35. Dane F, Gümüş M, Öztürk MA, Atasoy BM, İyikesici S, Yumuk PF, Başaran G, Abacioğlu U, Çabuk DÖ, Teomete, M ve **Turhal NS,** “Rektum Kanseri Olgularının Klinik Özellikleri ve Adjuvan Kemoradyoterapi Sonuçları: Tek Merkez Tecrübesi,” *2.Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı,* P23, Antalya, 2008. [Poster Bildiri Ödülü]

2.4.2.36. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D, İyikesici S, Yumuk PF, Başaran G, Abacioğlu U, Teomete M ve **Turhal NS,** “Türk Toplumunda Rektum Kanseri Hastaların Demografik, Histopatolojik Özellikleri, Sağ Kalım ve Prognostik Faktörler,” *5. Ulusal Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı,* B42, Antalya, 2008.

2.4.2.37. Atasoy BM, Dane F, Çağlar H, Cingi A, Abacioğlu U, **Turhal NS,** Şengöz M ve C. Yeğen, “Rezeke Edilebilir Lokal İleri Evre Rektum Kanserinde Preoperatif Radyoterapiyle Eş Zamanlı Floropirimidin Uygulaması: Oral mi, İntravenöz mü?,” *VIII. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı,* 184, Antalya, 2008.

2.4.2.38. Öztürk MA, Dane F, Çelikel ÇA, Baş E, Çabuk D, Yumuk PF, Başaran GA., Teomete M ve **Turhal NS,** “Adjuvan Kemoradyoterapi alan Kolorektal Kanseri Hastalarında Survivin Prognostik Önemi,” *18. Ulusal Kanseri Kongresi, Bildiri Özet Kitabı,* P135, Antalya, 2009.

2.4.2.39. Dane F, Öztürk MA, Gümüş M, Çabuk D, Yumuk PF, Başaran G, Teomete M, Korkmaz T, Şeber S, ve **Turhal NS,** “Metastatik Kolorektal Kanseri Tedavisinde Bevasizumab: Geç daha mı az etkin?,” *18. Ulusal Kanseri Kongresi, Bildiri Özet Kitabı,* P139, Antalya, 2009.

2.4.2.40. Dane F, Demir G, Öztürk MA, Yeğen C, Çabuk D, Başaran G, Yumuk PF, Teomete M, Korkmaz T, Şeber S ve **Turhal NS,** “Karaciğer ve akciğer metastazlı kolorektal kanseri hastalarında cerrahi rezeksiyon sonuçları,” *18. Ulusal Kanseri Kongresi, Bildiri Özet Kitabı,* P149, Antalya, 2009.

2.4.2.41. Atasoy BM, Dane F, Akgün Z, Çabuk D, Kabalay İA, Yumuk PF, Çağlar H, **Turhal NS** ve U Abacıoğlu, “Lokal ileri evre nazofarenks kanserinde dosetaksel ile sisplatin bazlı indüksiyon kemoterapisi sonrası sisplatinle eş zamanlı kemoradyoterapi: Sağkalım ve yan etki değerlendirmesi,” *18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı*, P236, Antalya, 2009.

2.4.2.42. Turhal NS, PF Yumuk, MS iyikesici, F Dane, **G Başaran**, M Ekenel, Bruce Avery. Knoxville, tennessee USA’de Evre III ve IV küçük hücreli dışı akciğer kanserli hastaların sonuçları. *18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı*, Ref 812; 72, Antalya, 2009

2.4.2.43. Adjuvan kemoradyoterapi (AKRT) alan kolorektal kanser (KRK) hastalarında survivinin prognostik önemi. Öztürk MA, Dane F, Demirel ÇA, Baş E, Çabuk D, Yumuk PF, Başaran G, Teomete M, **Turhal NS**, *Marmara Üniversitesi Tıp Fakültesi 3. Araştırma Günleri, İstanbul, Marmara Medical Journal* 22(1)(Ek 1) (2009), 6.

2.4.2.44. Başaran GA, Şeber S, Çabuk D, Korkmaz T, **Turhal NS**, Dane F, Başaran M, Koçak M, Telli F, Yumuk F. Erken evre meme kanserli hastalarda adjuvan trastuzumab tedavisi alan hastalarımızın klinik seyri. *III. Tıbbi Onkoloji Kongresi Bildiri Kitabı*, Poster 150, sayfa 97; 24-28 Mart 2010 Antalya

2.4.2.45. Şeber ES, Başaran G, Çabuk D, Korkmaz T, Koçar M, Telli F, Dane F, Yumuk F, **Turhal NS**. Trastuzumab sonrası progrese olan metastatik meme kanseri hastalarımızda lapatinib kullanımı. Erken evre meme kanserli hastalarda adjuvan trastuzumab tedavisi alan hastalarımızın klinik seyri. *III. Tıbbi Onkoloji Kongresi Bildiri Kitabı*, Poster 121, sayfa 84; 24-28 Mart 2010 Antalya

2.4.2.46. Çabuk D, Başaran G, Dane F, Korkmaz T, Şeber S, Telli F, Yumuk F, **Turhal NS**, metastatik meme kanseri hastalarının klinik özellikleri ve sağkalım sonuçları: Tek merkez deneyimi. *III. Tıbbi Onkoloji Kongresi Bildiri Kitabı*, Poster 146 sayfa 95; 24-28 Mart 2010 Antalya

2.4.2.47. Dane F, Öztürk MA, Ozkan M, Yıldız OG, Yaman E, Sevinç A, Atasoy BM, Gümüş M, Koçar M, Başaran G, Yumuk PF, **Turhal NS**. Günlük pratikte tedavi alan rektum kanseri hastalarının demografik sağkalım ve klinik/patolojik özellikleri: retrospektif bir kohort çalışması. *VII. Ulusal Tıbbi Onkoloji Kongresi. Kongre Bildiri Kitabı*. Poster 86, sayfa 139, 22-26 Eylül 2010, Antalya,

2.4.2.48. Dane F, Öztürk MA, Koçar M, Çabuk D, Teomete M, Korkmaz T, Seber S, Telli F, Kanitez M, Başaran G, Yumuk PF, **Turhal NS**. Müsin varlığı evre II kolorektal kanserlerde bağımsız bir risk faktörüdür. Kongre Bildiri Kitabı.poster no 88, sayfa 141 *VII. Ulusal Tıbbi Onkoloji Kongresi* 22-26 Eylül 2010, Antalya,

2.4.2.49. Dane F, Öztürk MA, Atasoy BM, Gümüş M, Koçar M, Çabuk D, Teomete M, Başaran G, Yumuk PF, Çelikel Ç, **Turhal NS**. Erken Evre rektum kanserlerinde perinöral invazyonun prognostik önemi. Kongre Bildiri Kitabı poster no 89, sayfa 142. *VII. Ulusal Tıbbi Onkoloji Kongresi* 22-26 Eylül 2010, Antalya,

Books written in Turkish

- 2.5.2.1. **Turhal NS**, “Antineoplastik İlaçları Kullanma Rehberi” İstanbul 1999.
2.5.2.2.

Books Chapters written in English

- 2.5.3.1. Biochemistry of Cancer, Medical Oncology Board Review, Williams & Wilkins, Philadelphia 1-42 March 1997.
- 2.5.3.2. Lung Cancer, Medical Oncology Board Review, Williams & Wilkins, Philadelphia 107-209 March 1997.
- 2.5.3.3. **Turhal NS**, Yumuk PF, “Tumor markers in neuroendocrine tumors of the gastroenteropancreatic system” İstanbul, 2004.

Book Chapters written in Turkish

- 2.5.4.1. Gümüş M, Atalay G, Aliustaoğlu M, **Turhal NS**, “Kolorektal Kanser (Bağırsak Kanseri) Hasta El Kitabı, İstanbul, 2000.
- 2.5.4.2. Atalay G, Aliustaoğlu M, Gümüş M, **Turhal NS**, “Meme Kanseri Hasta El Kitabı”, İstanbul, 2001.
- 2.5.4.3. Aliustaoğlu M, Gümüş M, Atalay G, **Turhal NS**, “Akciğer Kanseri Hasta El Kitabı”, İstanbul, 2001.
- 2.5.4.4. **Turhal NS**, “Özafagus kanserinde kemoterapi ve kemoradyoterapi uygulamaları” *Özafagus hastalıklarının tıbbi ve cerrahi tedavisi*, ed. Prof. Dr. Mustafa Yüksel, Prof. Dr. Ahmet Başoğlu, 321-329, İstanbul 2002.
- 2.5.4.5. **Turhal NS**, “Yüksek riskli gestasyonel trofoblastik tümörlerin tedavisi”, *Jinekolojik Kanserlerde Tedavi*, ed. N.M. Mandel ve M. Özgüroğlu, 89-96, Frekans, İstanbul, 2004.
- 2.5.4.6. Dane F, Ekenel M, Başaran G, İyikesici MS, Yumuk PF, Karamanoğlu A, **Turhal NS**. “Onkoloji Hastalarında Beslenme ve Egzersiz Rehberi” İstanbul 2004.

International Panelist/Speaker

2.7.1.1. “Approach to Colorectal cancer in Balkans”, *Balkan Congress of Oncology*, Serbia/Beograd, September 2004

2.7.1.2. “Current Approach to Hepatocellular Cancer” *Hazar University Multidisciplinary liver disease meeting*. Azerbaijan/Bakü, November 2004

2.7.1.3 “Current Treatment of Non-Hodgkin Lymphomas” King Faisal Medical Center. Saudi Arabia/Riyadh November 2005

2.7.1.4. “New approaches to the treatment of brain metastasis” *Turkish-Hellenic ESMO Advanced Course. Recent Advances in the Treatment of Cancer*. Turkey/Istanbul, December 2005

2.7.1.5. “Applications of Regenerative Medicine in Turkey” *Regional Health Conference “Balkan Medicine towards New Millenium”* Romania/Bcharest, May 2006

2.7.1.6. “New Research Efforts for Metastatic Gastric Cancer” *EORTC Gastrointestinal Tract Cancer Collaborative Group*, France/Paris, May 2006

2.7.1.7. Moderator, *Balkan School of Oncology, Second Seminar for Molecular Oncology in Cancer*. Greece/Volos September 2007.

2.7.1.8. Moderator, Innovative Therapeutic Approaches in Non-Colorectal Cancer, European Organization for research and Treatment of Cancer *Gastrointestinal Tract Cancer Collaborative Group*, Germany/Mainz November 2007

2.7.1.9. Moderator, Rare Gastrointestinal Tumors, Turkish-Hellenic 3rd ESMO Advanced Course Turkey/Istanbul December 2007

National Panelist/Speaker:

- 2.7.2.1. “Meme kanserinin kemik metastazlarının tedavisi”, *Türk Kanser ile Savaş Cemiyeti Toplantısı*, İstanbul, Temmuz 1998
- 2.7.2.2. “Meme kanserinin adjuvan hormon tedavisi”, *İstanbul Onkoloji Grubu Meme Kanseri Konsensus Paneli*, İstanbul, Şubat 1999
- 2.7.2.3. “Rezeke edilmiş akciğer kanserinde adjuvan kemoterapi” *İstanbul Onkoloji Grubu Akciğer Kanseri Konsensus Paneli*, İstanbul, Mart 1999
- 2.7.2.4. “Meme kanseri lokorejyonel relapsının tedavisi” *Cerrahpaşa Tıp Fakültesi*, İstanbul, Mayıs 1999.
- 2.7.2.5. “Over kanserinde optimal adjuvan tedavi” *İstanbul Onkoloji Grubu Jinekolojik Tümörler Konsensus Paneli*, İstanbul Mart 2000
- 2.7.2.6. “Meme kanserinde neo adjuvan kemoterapi”, *Gülhane Askeri Tıp Akademisi Toplantısı*, Ankara, Mayıs 2000
- 2.7.2.7. “HIV Kanserlerine Hemşire Yaklaşımı” *Marmara Üniversitesi Onkoloji Hemşireliği Konferansı*, İstanbul, Ekim 2000
- 2.7.2.8. “Küratif rezeke akciğer kanserinde takip” *Türk Göğüs Hastalıkları Derneği* İstanbul, Şubat 2001
- 2.7.2.9. “Rezeke edilmiş küçük hücreli dışı akciğer kanserinde takip” *İstanbul Onkoloji Grubu Akciğer Kanseri Konsensus Paneli*, İstanbul, Şubat 2001
- 2.7.2.10. “Duktal karsinoma insituda adjuvan tamoxifenin rolü” *Cerrahpaşa Tıp Fakültesi Meme Toplantıları* İstanbul, Nisan 2001
- 2.7.2.11. “Meme kanserinde seçici estrogen reseptör modülatörlerinin rolü”, *Türk Meme Cemiyeti*, İstanbul, Eylül 2001
- 2.7.2.12. “HIV kanserlerine hemşire yaklaşımı” *Marmara Üniversitesi Tıp Fakültesi Ulusal Onkoloji Hemşireliği Konferansı*, İstanbul, Ekim 2001
- 2.7.2.13. “Metastatik mesane kanserinin tedavisi” *Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi Tıp Günleri “Onkoloji”* İstanbul, Kasım 2001
- 2.7.2.14. “Meme kanserinin biyolojik tedavileri” *Gülhane Askeri Tıp Akademisi Onkoloji Toplantısı*, Ankara, Haziran 2002
- 2.7.2.15. “Erişkinlerde hodgkin hastalığının tedavisi”, *Ulusal Kanser Kongresi*, Antalya, Nisan 2003
- 2.7.2.16. “Disfajinin kanser hastalarındaki tedavisi”, *Türk Onkoloji Grubu Toplantısı*, Ankara, Mayıs 2003

- 2.7.2.17.** “Uluslar arası kanser arařtırmalarına katılımdaki güçlükler”, *Meme Bilimi (Senoloji) Derneđi*, İstanbul, Eylül 2003.
- 2.7.2.18.** “Meme kanserinin sistemik tedavisi”, *VII. Ulusal Meme Hastalıkları Kongresi*, Antalya, Ekim 2003
- 2.7.2.19.** “Gastroözafageal kanserlerde süren arařtırma projeleri”, *Sindirim Sistemi Kanserleri Çalıřma Grubu Toplantısı*, İzmir, Aralık 2003
- 2.7.2.20.** “Mide kanserinin adjuvan tedavisi” *Türk Onkoloji Grubu Toplantısı, Oturum başkanlığı*, Antalya, Aralık 2003
- 2.7.2.21.** “Kadınlarda sık görülen kanser türleri ve erken tanı” *Marmara Üniversitesi, Hemşirelik Müdürlüğü, 2004 Yılı Hizmet içi Eğitim Programı*, İstanbul, Şubat 2004.
- 2.7.2.22.** “Onkolojiye Giriř”, *Haydarpařa Numune Hastanesi Devamlı Eğitim Toplantıları*, İstanbul, Mart 2004
- 2.7.2.23.** “Yüksek riskli gestasyonel trofobilastik tümörlerde kemoterapi”, *Türk Onkoloji Derneđi Sürekli Eğitim Toplantıları*, Adana, Nisan 2004
- 2.7.2.24.** “Kanser ve mesleki maruziyet” *Meslek Hastalıkları ve İş Kazaları Kongresi*, İstanbul, Nisan 2004
- 2.7.2.25.** “HIV ve hodgkin dışı lenfoma”, *Türk Pediyatrik Onkoloji Kongresi*, Kayseri, Mayıs 2004.
- 2.7.2.26.** “Terminal kanser hastalarında bulantı tedavisi”, *Uluslararası Kanser Hastalarında Palyatif Bakım Kongresi*, İstanbul, Eylül 2004.
- 2.7.2.27.** “Beslenme ve mide kanseri” *Tıbbi Onkoloji Derneđi, Mide tümörleri Sempozyumu*” İstanbul, Aralık 2004.
- 2.7.2.28.** “Lokal ileri meme kanserinde güncel tedavi yaklaşımları” *İstanbul Tıp Fakültesi Meme Grubu IX. Mezuniyet Sonrası Eğitim Kursu* İstanbul, Aralık 2004.
- 2.7.2.29.** “Primeri bilinmeyen hastaya yaklaşım” *XVI. Ulusal Kanser Kongresi*. Antalya, Nisan 2005.
- 2.7.2.30.** “Etiology, pathogenesis, treatment and follow –up” *22. Ulusal Gastroenteroloji Haftası*. Malatya, Eylül 2005
- 2.7.2.31.** “Meme kanseri riskinin değerlendirilmesi ve korunma” *VIII. Ulusal Meme Hastalıkları Kongresi*. İstanbul, Eylül 2005
- 2.7.2.32.** “First line chemotherapy in advanced gastric cancer” *1. Ulusal Onkolojik Arařtırmalara çalıřtayı ve TOG Alt Çalıřma Grupları Toplantısı*. Ankara, Aralık 2005

2.7.2.32. “Küçük Hücreli Dışı Akciğer Kanseri-Lokal İleri Evre, Kemoterapi”
Akciğer, Meme, Gastrointestinal Sistem Kanserlerinde Konsensus Toplantısı. İstanbul,
Mart 2006

2.7.2.33. “Evre II Kolon Kanserinde Adjuvan Kemoterapi Gerekli mi?” *I. Tıbbi
Onkoloji Kongresi.* Antalya, Mart 2006

2.7.2.34. Bilimsel Kurul. *İstanbul Meme Kanseri Konferansı.* İstanbul, Eylül 2006.

2.7.2.34. “Disiplinlerin Birbirlerinden Beklentileri” *TAKD II. Ulusal Akciğer Kanseri
Kongresi.* Antalya, Kasım 2006

2.7.2.35. “Tedavi Uygulamalarına Bağlı Sorunlar” Oturum Başkanı. *5. İstanbul
Üniversitesi Onkoloji Enstitüsü Günleri.* Antalya, 30 Kasım – 3 Aralık 2006.

2.7.2.36. “Kolorektal Dışı Gastrointestinal Tümörlerde Hedefe Yönelik Tedaviler”
Tıbbi Onkoloji Derneği, Aralık 2006.

2.7.2.36. “Yeni Prognostik Faktörler ve Hedefe Yönelik Tedaviler” *3. Ulusal Torasik
Onkoloji Kongresi.* Marmaris, Haziran 2007.

2.7.2.37. Bilimsel Kurul. *9. Ulusal Meme Hastalıkları Kongresi.* Ankara Eylül 2007

International Meeting Organizations

- 2.8.1.1. *Uluslararası Kanser Hastalarında Palyatif Bakım Kongresi*, İstanbul, Eylül 2004.
- 2.8.1.2. European Organization for Research and Treatment of Cancer Gastrointestinal Study Group Meeting Istanbul Turkey 2005
- 2.8.1.3. Balkan Union of Oncology Biannual Meeting Izmir Turkey 2008

National Meeting Organizations

- 2.8.2.1. *Marmara Üniversitesi Onkoloji Hemşireliği Konferansı*, İstanbul, Ekim 2000
- 2.8.2.2. *Marmara Üniversitesi Tıp Fakültesi Ulusal Onkoloji Hemşireliği Konferansı*, İstanbul, Ekim 2001

Collaboration in National Research Projects

3.1.2.1. Mide kanserli hastaların yaşam kalitesini değerlendirmede EORTC QLQ-C30 ve hastalığa özel anket modülü olan (QLQ-STO 22)' nin güvenilirlik ve gerçekliği üzerine uluslararası bir saha araştırması, EORTC 15001/40003, *Sorumlu Araştırmacı*, 2002.

3.1.2.2. Rezeke edilemeyen karaciğer metastazlı kolorektal kanser hastalarında irinotekan+fluorouracil/leukovorin kombinasyon tedavisi sonrası rezeke edilebilirlik hızının değerlendirildiği klinik çalışma, çok merkezli TOD çalışması, *Sorumlu Araştırmacı* 2003.

3.2.2.1. Daha önce bir veya iki kemoterapi rejimi uygulanmış olan, ancak en son uygulanan kemoterapi rejimine cevap vermemiş ya da bu rejimi tolere edememiş, ileri evre, küçük hücreli-dışı akciğer kanserli hastalarda ZD1839 (Iressa™) (250mg tablet) + en iyi destek tedavisi kombinasyonunu, plasebo + en iyi destek tedavisi kombinasyonu ile karşılaştıran, plasebo kontrollü, çok-merkezli, randomize, faz III sağ kalım çalışması, Iressa/709 (ISEL) çalışması, *Yardımcı Araştırmacı*, 2003. **Puan: 15**

3.2.2.2. Adjuvan Kemoradyoterapi Uygulanan Rektum Kanseri Hastalarda Yaşam Kalitesinin Değerlendirilmesi, Faz IV, Ulusal, Çok Merkezli Çalışma, *Yardımcı Araştırmacı*, 2003.

3.2.2.3. Haftalık Paclitaxel ve Carboplatin tedavisi almış olan evre IIIA/B, IIIB (plevral effüzyonlu) ve IV küçük hücreli dışı akciğer kanseri hastalarında Her 2-neu ve TP53 tümör supressör geninin hastaların prognozuna katkıları olup olmadığının incelenmesi, *Yardımcı Araştırmacı*, 2004.

3.2.2.4. İndiferansiye ve Non-Keratinize Skuamöz Hücreli Nazofarenks Kanserinde Doseksel-Sisplatin Neoadjuvan Tedavisi Sonrası Kemoradyoterapi Uygulamasının Etkinliğinin Değerlendirildiği Faz IV Klinik Çalışma, TOG Baş-Boyun Grubu Çalışması, Ulusal, Çok Merkezli Çalışma, *Yardımcı Araştırmacı*, 2004.

3.2.2.5. Anastrozol (Arimidex) kullanan erken evre meme kanseri hastalarında elektronik farmakovijilans çalışması, *Yardımcı Araştırmacı*, 2004.

3.2.2.6. Taxotere ve Sisplatin ile birinci basamak kemoterapiyi takiben küçük hücreli olmayan akciğer kanserinin tedavi stratejisine ilişkin gözlem çalışması XRP6976C/9001 *Yardımcı Araştırmacı*, 2004.

Collaboration in International Research Projects

- 3.2.1.1.** Çok merkezli yüksek doz infüzyonel 5-FU±Folinik asit ile bolus 5-FU/folinik asitin karşılaştırıldığı randomize faz III çalışması, EORTC PETACC-2, *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2002
- 3.2.1.2.** 35 yaş altı meme tümörlü hastaların adjuvan tedavilere bağlı fertilitate kaybı riskine karşı tutumlarını değerlendirmeye yönelik Uluslararası Meme Grubunun ölçme çalışması, EORTC 10002, *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2003.
- 3.2.1.3.** Daha önce tedavi almamış ve platinum ile etoposid verilecek ekstensif evre küçük hücreli akciğer kanserli hastalarda darbopoetin alfa kullanımının etkisini ölçen randomize, çift-kör, plasebo kontrollü çalışma, *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2003.
- 3.2.1.4.** FACT: Anastrozol Monoterapisi ile Anastrozol+Fulvestrant kombinasyonu ile sağlanan maksimal östrojen blokajının karşılaştırılması: Hormon reseptörü pozitif meme kanseri olan ve lokalize tümörün primer tedavisinden sonra ilk defa nüks gelişen postmenapozal kadınlarda yalpan açık, randomize, karşılaştırmalı, çok merkezli faz III çalışma, Protokol no: 9238SW/0001, Uluslararası, Çok Merkezli Çalışma, *Marmara Üniversitesi için Sorumlu Araştırmacı* 2004.
- 3.2.1.5.** Lokal olarak gelişmiş veya metastatik meme kanseri olan postmenapozal kadınlarda birinci seçenek hormon tedavisinde letrozol ile kombine olarak oral CCI-779'a karşı tek başına letrozol uygulamasının karşılaştırıldığı bir faz III randomize plasebo kontrollü, çift kör çalışma, Protokol no: 3066A1-303-WW, *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2004.
- 3.2.1.6.** Menapoz sonrası metastatik meme kanseri hastalarında ilk seçim hormonal tedavi olarak exemestane ile tamoxifen kullanımının karşılaştırılması, randomize faz III çalışma, (EORTC Protokol No: 10951) *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2004.
- 3.2.1.7.** Hormona duyarlı meme kanseri olan premenopozal kadınlarda adjuvan tedavi olarak over fonksiyonunun baskılanması ve exemestanın rolünü değerlendiren bir faz III randomiz çalışma. Suppression of ovarian function trial (SOFT), Intergrup faz III çalışması; IBCSG 24-02, BIG 2-02, EORTC Protokol no 10031), *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2004.
- 3.2.1.8.** Post menopozal metastatik meme kanserinde birinci basamak tedavisi olarak Letrozol ile kemoendokrin tedavisinin eş zamanlı ve sıralı kullanımının Letrozol'ün tek ajan olarak kullanımıyla karşılaştırıldığı randomize çok merkezli çalışma; CFEM 345 C 2402 *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2004.
- 3.2.1.9.** Taksanlar ve Antrasiklin terapisinden sonra ilerleyen metastatik meme kanserli hastalarda 3 haftalık sikluslarda 2 hafta süreyle günde iki defa uygulanan kapesitabin (Xeloda) tabletleri ile 3 haftada bir IV uygulanan RPR109881'in karşılaştırıldığı randomize faz III çalışması. *Marmara Üniversitesi için Sorumlu Araştırmacı*, 2004.